Roles of manganese and protein kinase signaling in cell culture and animal models of prion disease by Martin, Dustin Paul
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2013
Roles of manganese and protein kinase signaling in
cell culture and animal models of prion disease
Dustin Paul Martin
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Neuroscience and Neurobiology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Martin, Dustin Paul, "Roles of manganese and protein kinase signaling in cell culture and animal models of prion disease" (2013).
Graduate Theses and Dissertations. 13388.
https://lib.dr.iastate.edu/etd/13388
  
Roles of manganese and protein kinase signaling in cell culture and animal 
models of prion disease  
 
by 
Dustin Martin 
 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
Co-majors: Molecular, Cellular, and Developmental Biology; Neuroscience 
 
Program of Study Committee: 
Anumantha G. Kanthasamy, Major Professor 
Arthi Kanthasamy 
Eric Rowe 
Jesse Hostetter 
M. Heather Greenlee 
 
Iowa State University 
Ames, Iowa 
2013 
ii 
 
TABLE OF CONTENTS 
 
CHAPTER 1. GENERAL INTRODUCTION          1 
Dissertation Organization            1 
Introduction              1 
Literature Review                6 
References           34 
 
CHAPTER 2. INFECTIOUS PRION PROTEIN ALTERS MANGANESE 
TRANSPORT AND NEUROTOXICITY IN A CELL CULTURE MODEL OF  
PRION DISEASE             57 
Abstract            58 
Introduction            60 
Materials and Methods         62 
Results           70 
Discussion           76 
Conflict of interest          81 
Acknowledgements          81 
References           82 
Figures           96 
 
iii 
 
CHAPTER 3. MANGANESE ALTERS CELLULAR DISTRIBUTION OF PRION 
PROTEIN AND EXPRESSION OF MAHOGUNIN IN CELL AND ANIMAL  
MODELS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY           103 
Abstract                   103 
Introduction                   105 
Materials and Methods                 109 
Results                   113 
Discussion                   118 
References                   121 
Figures                   132 
 
CHAPTER 4. PROTEOLYTIC ACTIVATION OF PROTEIN KINASE C DELTA 
CONTRIBUTES TO TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY-
RELATED NEURODEGENERATION                139 
Abstract                   139 
Introduction                   141 
Materials and Methods                 143 
Results                   149    
Discussion                   158    
References                   161 
Figures                   171 
 
iv 
 
CHAPTER 5. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS           192 
 References                   196 
 
1 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
Dissertation Organization 
 
This dissertation is written in an alternative thesis format and consists of 
manuscripts that have been published, in peer review, or are being prepared for 
submission. The references for the background and literature review section and 
each manuscript chapter are listed at the end of that specific section. 
  
This dissertation contains the experimental results obtained by the author 
during his graduate study under the supervision of his major professor, Dr. 
Anumantha G. Kanthasamy in the department of Biomedical Sciences, affiliated with 
the Neuroscience and Molecular, Cellular, and Developmental Biology 
Interdepartmental Graduate Programs at Iowa State University of Science and 
Technology. 
 
Introduction 
 
Despite several decades of dedicated research by a diverse array of 
researchers from around the globe, the molecular mechanisms underlying neuronal 
loss during transmissible spongiform encephalopathy (TSE) remain to be elucidated. 
Additionally, the etiology of so-called “sporadic” cases of TSE, which represents the 
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vast majority of cases in both humans and animals, remains unknown. Several 
recent advancements in the understanding of other protein misfolding 
neurodegenerative disorders including Alzheimer’s Disease (AD), Parkinson’s 
Disease (PD), Amyotrophic Lateral Sclerosi (ALS), and TSE have highlighted the 
similarities between disease etiopathogenesis which may broaden the diversity of 
potential future therapies. As our understanding of each disease state increases, the 
potential of advancements from one disease state applying to another is tantalizingly 
possible. Conversely, the public health implications of the discovery that AD, PD, 
and ALS may be transmitted in a prion-like manner highlight the urgency in 
elucidating the mechanisms underlying these devastating disorders. Although the 
metal binding capacity of PrPC and other amyloidogenic proteins is well 
documented, the environmental contribution to TSE pathogenesis, including the role 
of divalent metals such as manganese, is unknown. Herein we report that neuronal 
cells infected with TSE are less susceptible to Mn-induced toxicity than uninfected 
cells. Mn treatment also induces cytosolic localization of PrPC in cell and animal 
models, thus providing a mechanism that incorporates inhibition of the protein 
degradation machinery with metal dyshomeostasis. Additionally, we have discovered 
proteolytic activation of the delta isoform of protein kinase C (PKCδ) and changes in 
the phosphorylation of PKCδ at two regulatory sites in multiple brain regions in a 
mouse-adapted scrapie model. Knockout of PKCδ causes a significant delay in the 
onset of motor symptoms associated with TSE and an altered pattern of oxidative 
damage. These discoveries provide further mechanistic insight into TSE-related 
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neuronal degeneration. 
 
Metals and Neurodegenerative Disorders 
 
Our understanding of the role of metals in key neurobiological processes as 
well as in the pathogenesis of various neurodegenerative diseases has continued to 
expand over the last two decades. Although it is well known that elemental metals 
are required for normal functioning of cells, the degree at which the central nervous 
system (CNS) uses metals in synaptic signaling and the loss of metal homeostasis 
during neurodegenerative diseases was, until recently, unknown. Dyshomeostasis of 
transition metals such as iron, copper, and zinc have been implicated in major 
neurodegenerative conditions such as Parkinson’s disease (PD),  Alzheimer’s 
disease (AD), amyotrophic lateral sclerosis (ALS or Lou Gherig’s disease), and 
Huntington disease (HD) (Bishop et al., 2002; Bossy-Wetzel et al., 2004; Brown, 
2009; Bush and Curtain, 2008; Cahill et al., 2009; Gaeta and Hider, 2005; Molina-
Holgado et al., 2007; Sayre et al., 1999). Another common pathological feature of 
neurodegenerative diseases is aggregation of β-sheet rich proteins associated with 
each specific disease (e.g., α-synuclein in PD, a-beta and tau in AD, and huntingtin 
in HD) (Tyedmers et al., 2010). Alarmingly, the exposure of amyloidogenic proteins 
or their cleavage products to metals has been shown to induce their aggregation. 
Copper has been linked to aggregation of α-synuclein and a-beta (Brown, 2009). 
Zinc has been implicated in the aggregation of a-beta and manganese was shown to 
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seed aggregation of recombinant PrPC (Brown, 2009). Studies overwhelmingly 
demonstrate metal dyshomeostasis, protein aggregation, and oxidative stress are 
interconnected mechanisms key to the neurodegeneration in PD, AD, HD, and ALS. 
Despite this clear association, the molecular mechanisms underlying these 
phenomena are still poorly understood; however, a clearer picture is beginning to 
emerge. 
 
Molecular pathways of neurodegeration 
 
Although several of the major programmed cell death signals including 
extracellular receptors and internal stress receptors have been identified, the 
molecular pathways leading to DNA fragmentation, lysosome formation, and zeiosis 
continue to be a target of dedicated investigation. Various signaling pathways have 
been identified that involve tightly controlled cascades of posttranslational 
modifications of proteins that lead to apoptosis (Bossy-Wetzel et al., 2004). Many of 
the key molecules involved in these pathways, such as the proteolytic caspases, 
remain in a dormant state prior to the activation of the cell death cascade (Jellinger, 
2009). However, several proteins that serve normal endogenous functions within the 
cell are conscripted once the programmed cell death machinery has been activated. 
The delta isoform of protein kinase C has been implicated in cellular differentiation, 
proliferation, and secretion; however, cleavage by proapoptotic capspase-3 
separates the regulatory domain of the protein from the catalytic domain producing a 
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constitutively active kinase that can induce PCD (Kanthasamy et al., 2003; Reyland, 
2007). The disruption of the delicate interplay between these and other signaling 
pathways caused by TSE must be more clearly understood if effective treatments 
are to be designed.  
 
Are all proteinaceous neurodegenerative disorders prion diseases? 
 
 Recent evidence elucidated by multiple groups studying a variety of 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, 
and amyotrophic lateral sclerosis (ALS or Lou Gherig’s disease), have established 
the possibility that the pathogenic proteins implicated in each of these diseases are 
prions as well. Specifically, α-synuclein, tau, and Mn-superoxide dismutase, the 
amyloidogenic proteins associated with Parkinson’s disease, Alzheimer’s disease, 
and amyotrophic lateral sclerosis, respectively, can catalyze the conversion from 
their endogenous conformation to their disease isoforms and can therefore be 
considered prions (Jucker and Walker, 2011; Lee et al., 2010; Moreno-Gonzalez and 
Soto, 2011; Walker and LeVine, 2012). Our group has focused on understanding the 
molecular pathways of neurodegeneration in Parkinson’s disease in an effort to 
elucidate the etiology of the disease and to provide targets for pharmaceutical 
intervention. In an effort to more clearly understand the multilayer connectivity 
amongst neurodegenerative diseases, we examined the consequence of metal 
dyshomeostasis and kinase signaling on the progression of TSE-related 
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neurodegeneration.  
 
Conclusion of background information 
 
Classically, “TSE” and “prion disease” have been used interchangeably to 
refer to the multitude of diseases caused by the infectious isoform of prion protein 
(PrPSc). This choice of nomenclature must be reevaluated since it is clear that many, 
if not all, amyloidogenic proteins associated with neurodegenerative disorders are 
transmissible pathogens. For the purposes of this document, TSE will refer to the 
prion disease caused by pathogenic misfolding of the prion protein.  
 
Literature Review 
 
Prion Protein 
 
 The endogenous prion protein (PrPC) is ubiquitously expressed with the 
highest concentrations in the central nervous system (CNS) and lymphatic system, 
although its biological function still remains unclear. PrPC has been suggested to 
function as an antioxidant, a cellular adhesion molecule, a signal transducer, and a 
metal binding protein (Brown, 2004; Chen et al., 2003; Chiarini et al., 2002; Mange 
et al., 2002; Sakudo et al., 2004). While the function of the PrPC is not well defined, 
the hallmark of transmissible spongiform encephalopathy (TSE) is conversion of the 
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soluble α-helix rich form of cellular  PrPC to the insoluble β-sheet rich infectious 
isoform of the protein (PrPSc) through a still unknown mechanism (Bolton et al., 
1985; Collinge, 2005; Prusiner and DeArmond, 1990). The Prnp gene is found on 
chromosome 20 in humans and encodes for a 254 amino acid sequence before 
processing (Kretzschmar et al., 1986). The first 22 amino acid residues of the N-
terminus are cleaved shortly after translation, and the last 23 amino acid residues of 
the C-terminus are cleaved prior to the addition of a glycophosphatidylinositol (GPI) 
anchor (Kretzschmar et al., 1992; Stahl et al., 1987). Properly folded prion protein is 
present on lipid membrane rafts, and is believed to be internalized via clathrin-
mediated endocytosis with a half-life of about 3 hrs (Nunziante et al., 2003; Peters et 
al., 2003; Prado et al., 2004). Internalized PrPC is rapidly degraded via the ubiquitin 
proteasomal system (UPS) or recycled back to the cell surface (Ciechanover and 
Brundin, 2003; Kang et al., 2004; Laszlo et al., 1992). PrPC is a highly conserved 
protein among mammals, with protein homology scores greater than 90% in all 
observed species (Martins and Brentani, 2002).  
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Figure 1 Overview of TSE 
 
Prion Disease and TSE 
 
Prions are pathogenic molecules formed solely from misfolded isomers of 
endogenous proteins (Alpers and Isselbacher, 1967; Prusiner, 1982). Prions act as a 
template to induce the misfolding of normal conformers to the pathogenic isoform, 
that can then propagate more conversions, yet the mechanism by which this change 
occurs is unknown. Transmissible spongiform encephalopathy (TSE) is a fatal 
neurodegenerative disorder caused by misfolding of the endogenous prion protein 
(PrPC) induced by exposure to the pathogenic conformational isomer of PrP (PrPSc) 
or by heritable mutation of PrPC (Prusiner, 1991a; Prusiner, 1991b; Prusiner, 1991c). 
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TSE affects both humans and animals, and transfer between species has been 
recorded (Belay and Schonberger, 2005). TSE is characterized by accumulation of 
aggregated, proteolytically-resistant PrPSc, gliosis, neuronal loss, and vacuolation of 
the CNS (Belay and Schonberger, 2005; Wadsworth and Collinge, 2011). When 
examined histologically, the neuronal loss and vacuolation observed in TSE gives 
affected tissue a diagnostic spongy appearance. Reactive astrocytic gliosis, 
microglial activation, and spongiform degeneration co-localize with accumulation of 
PrPSc in vivo (DeArmond et al., 1987). Interestingly, different conformational isomers 
with identical primary sequences can display widely varying pathology indicating that 
the secondary and tertiary structure of PrPSc can encode different strains of TSE 
(Gambetti et al., 2011; Parchi et al., 2010; Weissmann et al., 2011). Recent findings 
have uncovered the possibility that the amyloid plaque forming proteins involved in 
Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis are 
prions as well (Braak and Del Tredici, 2011; Desplats et al., 2009; Guo and Lee, 
2011; Kordower et al., 2008; Munch et al., 2011). A detailed understanding of the 
prion mechanism that leads to protein aggregation and accumulation may help 
demystify the etiology of all amyloidogenic neurodegenerative disorders. 
 
TSE and public health 
 
The unique nature of the proteinaceous pathogen that is the causative agent 
of TSE is highly resistant to classic sterilization methods that affect nucleic acids 
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(Bellinger-Kawahara et al., 1987; Gibbs et al., 1978). Additive to this is the 
resistance of PrPSc to denaturation and proteolysis (Prusiner et al., 1980). Iatrogenic 
transmission of PrP through blood transfusions and grafts of human tissue have 
been confirmed (Belay and Schonberger, 2005). PrPSc binds readily to metal 
surfaces such as stainless steel surgical instruments and can be readily transmitted 
if not properly decontaminated (Flechsig et al., 2001; Zobeley et al., 1999). 
Insidiously, exposure of normal uninfectious brain homogenate to steel wires 
produced de novo infectious PrPSc that could be transmitted to animals (Edgeworth 
et al., 2010). This spontaneous mechanism of PrPSc generation clearly demonstrates 
the need to better understand the pathogenesis of this diabolical disease. 
 
Characterization of prion disease 
 
 Pathogenically misfolded PrPSc has been identified as the causative agent of 
TSE, yet the various forms of this disease do not share a common etiology or 
pathology. Studies have demonstrated that PrPC undergoes a conversion from 
endogenous membrane-bound protein to a misfolded transmissible 
neurodegenerative pathogen through changes to its secondary and tertiary structure 
by an as yet unidentified process (Prusiner, 1982).  Both exposure to pathogenic 
PrPSc and mutations within PrPC have been shown to cause TSE (Belay and 
Schonberger, 2005).  
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Figure 2 Schematic of PrPC 
 
PrPC structure and function 
 
Endogenous PrPC is a glycophosphatidylinositol anchored membrane protein 
located primarily in lipid raft domains (Lakhan et al., 2009; Naslavsky et al., 1997; 
Stahl et al., 1987). Structural studies have suggested that the N-terminus of prion 
protein is unstructured, while the C-terminus is highly structured, with two α-helices 
linked via disulfide bond, a shorter α-helix, and two short strands of β-sheet 
structures (Di Natale et al., 2005; Jones et al., 2005; Renner et al., 2004; Viles et al., 
2001). The C-terminal domain also contains two N-linked glycosylations on the 
asparagines in positions 181 and 197 (mouse numbering); however, the protein is 
found in unglycosylated, monoglycosylated, and diglycosylated forms that produce 
three distinct bands in immunoblot assays (Kretzschmar et al., 1986). The role the 
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glycosylations play in the endogenous function of the protein, if any, is currently 
unknown. However, a recent study has shown the glycosylation state of PrPC does 
not affect the metal binding affinity of PrPC (Davies and Brown, 2009).  
Although the metal binding capacity of PrPC has been demonstrated by 
multiple studies, the endogenous function of PrPC is still a matter of debate. It has 
been suggested to function as an antioxidant, a cellular adhesion molecule, a signal 
transducer, and a metal regulatory protein (Brown, 2004; Chen et al., 2003; Chiarini 
et al., 2002; Mange et al., 2002; Sakudo et al., 2004). Cu bound to the N-terminus of 
PrPC is able to undergo full and reversible redox chemistry, which allowed for the 
detoxification of superoxide and the reduction of hydroxyl radicals in in vitro assays 
(Nadal et al., 2007). A variety of approaches have identified possible ligands for 
PrPC. PrPC interacts with the cell adhesion molecules NCAM and lamanin to 
promote neurite outgrowth (Beraldo et al., 2011; Santuccione et al., 2005). The 
interaction of PrPC and stress inducible protein 1 (STI1) has been linked to the 
induction of cell survival under apoptotic stress and the modulation of both short and 
long term memory performance (Coitinho et al., 2007; Zanata et al., 2002).  Although 
GPI anchored PrPC does not contain an intracellular domain, initial studies found 
that the binding of anti-PrP antibodies to cell surface PrPC induced a calveolin-
dependent coupling of PrP to Fyn kinase that resulted in an increase in Fyn kinase 
activity (Mouillet-Richard et al., 2000). Binding of PrPC specific antibodies to surface 
PrPC has also been shown to selectively modulate 5-HT receptor signaling (Mouillet-
Richard et al., 2005). Induced dimerization of PrPC through binding of the anti-PrP 
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antibody 6H4 in human neurons resulted in alterations of the mitogen activated 
protein kinase (MAPK) signaling pathways (Arsenault et al., 2012). Additionally, in 
the same study a peptide corresponding to residues 106-126 of PrPC activated 
growth factor related signaling pathways including vascular endothelial growth factor 
(VEGF) signaling and the phosphoinositide-3 kinase (PI3K) pathway. Recent 
evidence has also linked PrPC signal transduction to Alzheimer’s disease 
pathogenesis. In this study, Aß was shown to directly interact with cell surface PrPC 
to modulate the distribution of NMDA receptors through a Fyn kinase-dependent 
mechanism (Um et al., 2012; Um and Strittmatter, 2012). These studies and others 
indicate that PrPC must interact with a transmembrane signaling protein to transmit 
information into the cell; however the identity of this elusive molecule or molecules 
remains a mystery. 
 
Aggregation and amyloidogenesis of PrPSc 
 
 Similar to other amyloidogenic proteins, PrPSc often undergoes truncation 
prior to the formation of amyloid fibrils (Kitamoto et al., 1991). Sequencing of 
peptides obtained through purification of amyloid plaques found in GSS using formic 
acid identified the amyloid core of PrPSc resides in the PrPSc binding domain 
between residues 90-140 (Piccardo et al., 1996). The structure of the amyloid-
forming domain in PrPSc is believed to be a left-handed ß-helix (Govaerts et al., 
2004). This ß-helix structure allows PrPSc to form trimers through hydrophobic 
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interactions that can then stack vertically forming unbranched fibrils. The amyloid 
plaques in TSE are stained strongly by classical amyloid-staining dyes such as 
thioflavin T, and congo red (Ishikawa et al., 2004). 
 Despite the ability to form amyloid, mature amyloid plaque formation in TSE is 
a relatively rare occurrence. Only the rare familial mutations resulting in GSS, the 
isolated cases of kuru, and 5-10% of CJD cases are associated with amyloid plaque 
deposition (Ghetti et al., 1995; Hainfellner et al., 1997; Kovacs et al., 2002; Liberski 
and Brown, 2004). The vast majority of TSE cases in humans and animals are 
associated with little to no amyloid. This lack of amyloid accumulation in TSE 
indicates that cerebral amyloidosis is unlikely to cause the neuronal dysfunction and 
death found in TSE. Studies have shown that aggregations of non-fibrilliar PrP 
oligomers are neurotoxic (Soto and Satani, 2010), and can spread from cell to cell 
through direct cell to cell contact and by release into the intercellular media (Fevrier 
et al., 2004; Kanu et al., 2002). Transmission and propagation of aggregated PrPSc 
through both synapses and actin-rich intercellular nanotubes has been observed 
(Gousset et al., 2009; Magalhaes et al., 2005). Small aggregated oligomers of PrPSc 
were determined to be more infectious than monomeric or amyloid PrPSc (Silveira et 
al., 2005). Formation of a transient oligomeric core may precede formation of 
amyloid fibrils when they do occur (Ohhashi et al., 2010). Accumulation of amyloid 
plaques may in fact be a neuroprotective strategy used by the CNS to deal with 
misfolded proteins that are resistant to normal degradation pathways.  
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Metal binding affinity of PrPC 
 
 Octapeptide Repeat Domain: PrPC contains several octapeptide repeat 
sequences (PHGGSWGQ) toward the N-terminus, which have binding affinity for 
divalent metals such as copper, manganese, and zinc, with preferential binding for 
copper (Hornshaw et al., 1995; Viles et al., 1999). The number of octapeptide 
repeats differs from species to species. For example, humans, mice, sheep, and 
deer each have five octapeptide repeats in the wild type protein while bovine PrP 
has six (Mastrangelo and Westaway, 2001). Mutation of the prion protein gene 
including point mutations, deletions, or multiple insertions of the octapeptide repeats 
have been linked to inherited prion disease in humans (Mead et al., 2007; Yin et al., 
2007) A higher number (up to 14) of repeats has been associated with the human 
form of the prion disease known as Gerstmann-Sträussler-Sheinker (GSS) 
syndrome (Krasemann et al., 1995; Palmer and Collinge, 1993). Binding of divalent 
cations to the octapeptide repeats has been speculated to facilitate the folding of the 
unstructured N-terminus, resulting in stabilization of the protein conformation 
(Cereghetti et al., 2003).  
Recent studies have shown disease associated mutations in octapeptide 
repeats are critical for divalent metal-induced protein turnover and internalization by 
endocytosis, suggesting that octapeptide repeats in prion protein can alter the 
homeostasis of the divalent metal pool in the cell (Stevens et al., 2009). Studies 
using electron resonance imaging and X-ray crystallography on recombinant 
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octapeptide fragments have shown that a single copper is bound by each full 
octapeptide repeat segment in a pentacoordinate complex involving residues 
HGGGW (Aronoff-Spencer et al., 2000; Burns et al., 2002; Burns et al., 2003). 
Further studies on Cu coordination with the octapeptide repeat domain have shown 
that there are three distinct modes at physiological pH (Chattopadhyay et al., 2005). 
The antioxidant activity of PrPC requires Cu bound within the octapeptide repeat 
domain (Brown et al., 1999; Brown et al., 2001; Gaggelli et al., 2008; Treiber et al., 
2007). Cu bound by the octapeptide repeat domain of PrPC is able to undergo full 
and reversible redox chemistry and can function to detoxify superoxide and reduce 
hydroxyl radicals (Nadal et al., 2007). Loss of this antioxidant activity may 
exascerbate neurodegeneration in TSE. Additionally, transgenic mice expressing 
PrPC devoid of the octapeptide repeat domain showed greater susceptibility to 
ischemic injury when compared to wild type mice (Mitteregger et al., 2007).  
The endocytosis of the PrPC upon binding Cu was shown in a series of 
experiments in which the PrPC null mouse hybridoma cell line F14 was transfected 
with a variety of Prnp mutants fused with GFP (GFP-PrPC) and their response to 
copper was measured. F14 cells transfected with normal GFP-PrPC showed a loss 
of cell surface fluorescence when exposed to copper, indicative of internalization, 
while cells expressing a form of PrP truncated from residues 38-231 did not. 
Conversely, chelation of divalent metals by the selective resin chelex caused an 
increase in surface fluorescence. Mutants in which the octapeptide repeats were 
knocked out (∆51-90) and mutants in which there is one copy of the OR (∆67-90) 
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showed no change in cell surface fluorescence upon Cu treatment while ∆67-90 
showed a decrease less significant than GFP-PrPC but more significant than ∆51-90. 
These results showed that one octapeptide repeat was enough to rescue PrP 
internalization. Manganese and zinc were also tested but no statistical difference in 
cell surface fluorescence was seen (Haigh et al., 2005).  
Interestingly, the N-terminal domain is not required for conversion from PrPC 
to PrPSc. Using a scrapie infected N2a mouse neuroblastoma cell model, the 
octapeptide repeat region was determined to have no effect on conversion from 
PrPC to PrPSc in a chimeric mouse-Syrian hamster construct of the Prnp gene. All 
variations of the octapeptide repeat region tested showed persistent infection by 
PrPSc (Rogers et al., 1993).  
 
5th Site: As indicated above, PrPC is a putative metalloprotein since the 
octapeptide repeat sequences in the protein have high affinity for divalent cations 
including copper, manganese, and zinc, and the binding sites are suggested to play 
a role in the pathogenesis of prion diseases (Brown et al., 1997; Hesketh et al., 
2007; Hornshaw et al., 1995; Moore et al., 2006). Initial studies on Cu occupancy 
indicated that while 5 atoms of Cu were bound to PrPC, the octapeptide repeat 
domain only accounted for 4 atoms, arguing for a so called “5th site”. Additional 
higher affinity metal binding sites were identified at His 95 and 110 (mouse 
numbering) (Jackson et al., 2001; Jones et al., 2004). While His 110 appears to be 
the highest affinity site for Cu binding, His 95 was apparently required for the binding 
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of Mn (Brown, 2009).  
Studies using recombinant PrPC have shown that Mn can irreversibly replace 
Cu bound to PrPC, despite an apparent lower affinity, and this replacement causes 
conformational changes within the protein (Brazier et al., 2008; Zhu et al., 2008). 
Recombinant PrPC refolded in the presence of Mn was originally thought to bind up 
to four molecules of Mn at the octapeptide repeat domain, similar to Cu (Brown et 
al., 2000). However, isothermal titration calorimetry experiments have demonstrated 
that PrPC binds two molecules of Mn at each each at two different sites, with 
dissociation constants of 63 and 200 µM (Brazier et al., 2008). In comparison, 
divalent metal transporter 1 (DMT-1), a known transporter of Mn across the plasma 
membrane, was shown in kinetic studies of Mn uptake to transport Mn in mM 
concentrations (Garrick et al., 2006). Interestingly, the higher affinity binding site was 
not the octapeptide repeat domain, but the so called “5th site”. This study went on to 
show that Mn is able to replace Cu in Cu saturated PrP, even though PrP has a 
higher affinity for Cu at both binding sites (Brazier et al., 2008). The binding of Mn to 
PrPC was irreversible, as was the oxidation of Mn bound to PrPC.  
The biological consequence of Cu replacement by Mn on the prion protein is 
still unknown. However, molecular studies using circular dichroism and Raman 
optical activity indicate that upon PrP binding to Mn, the secondary structure 
becomes more organized, gaining greater α-helix and β-sheet content than Cu-
bound PrP (Brazier et al., 2008; Zhu et al., 2008). Limited proteolytic digestion 
experiments using proteinase K have shown Mn-bound PrPC gains partial protease 
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resistance, similar to, but less profound than the diagnostic proteolytic resistance 
characteristic of PrPSc (Brown et al., 2000; Kim et al., 2005). Once bound to Mn, PrP 
can also seed polymerization of soluble oligomers of metal free PrP (Abdelraheim et 
al., 2006; Giese et al., 2004). Most studies evaluating prion-Mn interactions were 
conducted in cell free systems using recombinant protein; however, the role of Mn in 
the pathogenesis of TSE has not been systematically studied and is currently 
unknown. Understanding the mechanisms of manganese interaction with prion 
protein may help to elucidate the pathophysiological mechanisms of prion diseases.   
 
Manganese and TSE 
 
The essential elemental metal Manganese (Mn) is required by organisms as 
an enzymatic cofactor for normal functioning; however, Mn dyshomeostasis results 
in adverse neurological deficits (Aschner, 1999; Dobson et al., 2004; Levy and 
Nassetta, 2003; Pfeifer et al., 2004). Prolonged exposure to high concentrations of 
Mn results in an irreversible neurological disorder called manganism (Beuter et al., 
1994; Gibbs et al., 1999; Myers et al., 2003). Early signs of manganism are 
associated with psychiatric disturbances, while later signs include rigidity, 
bradykinesia, dystonia, and ineffectiveness of levo-dopa therapy (Beuter et al., 1994; 
Dobson et al., 2004; McMillan, 1999).  Several lines of evidence suggest that 
exposure to Mn or Mn-containing compounds induces a variety of cellular changes 
including mitochondrial dysfunction, increased oxidative stress, glutathione and 
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dopamine depletion, impairment of energy metabolism and antioxidant systems, and 
alterations in various cell signaling pathways (Erikson and Aschner, 2003; Kitazawa 
et al., 2002; Roth and Garrick, 2003).  
Elevated Mn levels in the brain and blood of humans and animals afflicted 
with TSE have been observed. In particular, altered Mn content has been observed 
in the blood and brain of humans infected with Crueztfelt-Jacob Disease (CJD), mice 
infected with scrapie, and in cattle infected with bovine spongiform encephalopathy 
(BSE). Additionally, Mn-bound PrPSc can be isolated from both humans and animals 
infected with TSE, again despite a lower affinity than copper (Hesketh et al., 2007; 
Hesketh et al., 2008; Thackray et al., 2002; Wong et al., 2001).  
Our group has shown that PrPC interacts directly with the metal to protect 
cells from Mn toxicity, and Mn exposure increases PrPC protein levels independent 
of transcriptional upregulation. Our studies demonstrated that PrPC protects against 
Mn-induced neurotoxicity in mouse neural cells that do not express PrPC (PrPko). 
We found PrPC expressing cells are more resistant to Mn-induced cytotoxic and 
apoptotic cell death, and accumulated less Mn compared to PrPko. Also, Mn-
induced increases in ROS production, caspase-3 and -9 activation, and DNA 
fragmentation were significantly lower in PrPC cells compared to PrPko cells. 
Further, the significantly reduced Mn uptake in PrPC cells suggested that PrPC might 
act as a metal sink, thereby preventing Mn from entering the cells and exerting its 
neurotoxic effect. Furthermore, we found Mn treatment significantly altered the 
turnover of PrPC. Pulse chase experiments confirmed that the half-life of PrPC in Mn-
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treated cells was significantly increased (Choi et al., 2007; Choi et al., 2010). 
In addition, neuronal cells persistently infected with PrPSc were found to be 
more susceptible to oxidative stress (Fernaeus et al., 2005; Milhavet et al., 2000). 
Therefore, it was believed that the loss of this protective mechanism upon 
conversion from PrPC to PrPSc may contribute to the neurodegeneration associated 
with spongiform encephalopathy. However, information uncovered by the author and 
presented in the first research chapter showed that infection by PrPSc actually 
conferred protection from Mn neurotoxicity. The octapeptide domain of PrPC may be 
required for the Mn-induced increase in stability and accumulation of the protein. 
Studies using in vitro neuronal cells expressing N-terminally truncated forms of PrPC 
show increased toxicity with Cu and Mn treatments (Haigh and Brown, 2006). Zinc, 
iron, and nickel were also tested in these studies, but no significant difference was 
found. Since PrPC serves as a template for propagation of TSE upon scrapie 
infection, Mn-induced stabilization of PrPC may accelerate conformational 
conversion of PrPC to PrPSc. Whether the increase in Mn concentration observed in 
the brain during the progression of TSE in humans and animals is a key step in the 
pathogenesis of TSE or is a result of impaired homeostatic regulatory systems, 
including altered metal binding upon conversion to PrPSc, remains to be determined. 
Further studies are underway to elucidate the role of the octapeptide repeat domain 
and 5th site in Mn-induced changes in PrPC and the role Mn binding plays in the 
pathogenesis of the disease. 
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Environmental contributions to TSE etiology and pathogenesis 
 
Environmental exposure to transition metals has been linked to the 
pathogenesis of various neurodegenerative disorders (Migliore and Coppede, 2009). 
Metal neurotoxicity often exacerbates the degenerative changes that occur during 
these diseases, including ionic imbalance, oxidative stress, and protein aggregation 
(Bowman et al., 2011; Brown, 2004; Perl and Good, 1991). The amyloidogenic 
proteins implicated in the pathology of PD, AD, ALS, and TSE have all been shown 
to bind divalent metals (Brown, 2009). Additionally, these proteins are believed to 
have a role in maintaining metal homeostasis within the cell. The dysregulation of 
metal homeostasis observed in the terminal stages of neurodegenerative disorders 
highlights the involvement of metals in the molecular pathways of neurodegeration. 
To date, the vast majority of work done to elucidate the mechanisms of TSE 
pathogenesis has focused on the genetic determinants and biophysical kinetics of 
protein aggregation. A more detailed understanding of the environmental 
contributions, including the role of metals, will enable the development of effective 
treatment strategies for these debilitating diseases.  
Sporadic cases of TSE in humans and animals are thought to arise from 
“thermodynamically unlucky” folding of PrPC to a pathogenic isoform. However, the 
environmental contribution to TSE etiology has received less attention than the 
genetic and molecular determinants of pathogenesis. Exposure to organophosphate 
pesticides has been hypothesized to induce structural changes within PrP leading to 
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TSE pathogenesis (Purdey, 1996). However, studies using cell culture and mouse 
models of TSE using the organophosphate compounds phosmet and dimethoate 
have failed to find any increase in ß-sheet content or PrP aggregation, nor was the 
course of TSE changed as a result of treatment with these compounds (Shaw et al., 
2002). Interestingly, phosmet exposure did increase the level of cell surface PrPC in 
human neuroblastoma cells independent of transcription (Gordon et al., 1998).  
Studies have identified a correlation with low levels of Cu and high levels of 
Mn as potential environmental risk factors leading to the onset of sporadic TSE in 
animals (Davies and Brown, 2009; Purdey, 2000). A study of monozygotic twins with 
a pathogenic hereditary mutation to PrP developed TSE pathology seven years 
apart from each other (Bowman et al., 2011). These findings argue strongly for the 
possibility of an environmental determinant to the onset of TSE. The recurrence of 
TSE in livestock despite multiple governmental programs designed to eradicate the 
disease argues for the persistence of the pathogen in the environment. A correlation 
between soil clay content and incidence of chronic wasting disease in elk has been 
discovered indicating that soil constituents may affect the persistence of PrPSc in the 
environment (Johnson et al., 2007). A recent study found that infectious PrPSc can 
persist in soils for at least two years (Davies and Brown, 2009). Additionally, the 
presence of high levels of Mn in soils not only protects the protein from degradation, 
but may actually increase infectivity by up to 100-fold. These studies provide a route 
whereby PrPSc derived from carcasses or farm runoff can enter into the environment. 
Then oral inoculation of ruminants can occur through ingestion of soil microparticles 
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while grazing. The retention of infectivity in the environment seems to depend 
heavily on the composition of the soil and a greater understanding of these 
determinants would greatly help in assessing the risk factors of TSE.  
It seems clear that exogenous environmental variables are determinants that 
contribute to the spread of sporadic TSE and other neurodegenerative disorders 
including Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral 
sclerosis. Without a greater understanding of these variables, the risk factors and 
appropriate countermeasures cannot be accurately predicted. The contribution of 
divalent metals to pathogenesis remains an important area of study for all 
neurodegenerative diseases. Therefore the environmental contributors to the 
etiology of one neurodegenerative disorder may have implications for each. 
 
The ubiquitin proteosome system  
 
Ubiquitination is a tightly controlled cellular process that is involved in 
degradation of proteins, protein trafficking, and signaling. The first step in the 
addition of the 76 amino acid-long ubiquitin peptide to a substrate is the activation of 
ubiquitin by an E1 enzyme by adenylation of the C-terminus in an ATP dependent 
manner and the formation of a thioester bond to a catalytic Cys residue. The 
activated ubiquitin is then transferred to an E2 conjugating enzyme through a 
second thioester bond. The E2 enzyme then binds an E3 ubiquitin ligase that will 
attach the activated ubiquitin or ubiquitin-like peptide to a lysine residue on the 
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protein substrate. The E3 enzyme can then covalently attach subsequent ubiquitin 
molecules to any of the seven internal lysines (Lys-6, Lys-11, Lys-27, Lys-29, Lys-
33, Lys-48 and Lys-63) on the first forming a poly ubiquitin chain.  (Clague and Urbe, 
2010; Mukhopadhyay et al., 2007; Tyedmers et al., 2010; Whatley et al., 2008).  
Poly ubiquitin chains are classically associated with marking proteins for 
degradation by the 26S proteosome; however monoubiquitination of proteins and 
some specific polyubiquitination motifs are involved in DNA repair, protein 
localization, endosomal trafficking, and autophagic protein degradation 
(Mukhopadhyay et al., 2007; Sarge and Park-Sarge, 2011). Specificity between 
substrates appears to be encoded in the specific pairing of E2-E3 enzymes since 
only two human E1s have been identified, whereas 40 different E2 and over 600 E3 
enzymes have been found (Deshaies and Joazeiro, 2009). The fate of the target 
protein is largely determined by which lysine residue subsequent ubiquitins are 
attached to within the polyubiquitin chain, although the exact signals and E1-E2-E3 
proteins involved in each process are still a subject of ongoing research.  
 
UPS dysfunction in proteinopathies 
 
Although the etiology and pathogenesis of AD, PD, ALS, HD, and TSE differ, 
one of the pathological similarities shared between all proteinacious 
neurodegenerative disorders is accumulation of insoluble protein aggregates in intra- 
or extracellular inclusion bodies. These inclusions are largely formed by a single 
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protein constituent that is associated with the pathogenesis of the specific disease. 
The constituents of the disease-associated inclusions are often ubiquitinated, yet are 
not degraded by the UPS (Ardley and Robinson, 2004; Kang et al., 2004; Sarge and 
Park-Sarge, 2011). Monoubiquitination of proteins has been determined to act as a 
signal for protein sorting to intracellular vesicles (Mukhopadhyay et al., 2007; Sarge 
and Park-Sarge, 2011); however, a detailed understanding of the trafficking and 
quality control of amyloidogenic proteins through the UPS remains recondite. 
Intracellular protein aggregates have been shown to directly inhibit UPS function, 
causing a feedback loop that may exacerbate UPS dysfunction during the course of 
disease pathogenesis (Bence et al., 2001; Bennett et al., 2005; Holmberg et al., 
2004) . 
 
Mahogunin RING-finger 1 is an E3 ubiquitin ligase 
 
The E3 ubiquitin ligase mahogunin RING-finger 1 (Mgrn1) contains a C3HC4 
RING-finger Zn-binding domain, similar to other zinc finger ubiquitin ligases (He et 
al., 2003b; Phan et al., 2002). The gene sequence has two alternative exons that 
produce four alternate splice variations of 532, 554, 556, and Mgrn1 has displayed 
both mono- and polyubiquitination activity in both in vitro and in vivo models (Jiao et 
al., 2009; Phan et al., 2002). Although E3 ubiquitin ligases encode specificity for 
specific substrates, Mgrn1 has been implicated in a vast array of functions outlined 
below. 
27 
 
 
Mgrn1 was first identified as a downstream accessory protein involved in 
pigment type switching through the G-protein coupled receptor, melanocortin-1 
(Mc1r), in hair follicle melanocytes (He et al., 2003a; Miller et al., 1997). First dubbed 
mahoganoid (md/md), this spontaneous mutation produced animals with a black 
coat even in the presence of the normally yellow gain of function mutations of the 
agouti gene (Miller et al., 1997). Discovered in conjunction with mahogany, which 
was later identified as the mouse ortholog for the human gene attractin (Atrn), both 
are downstream modulators for the production of the pigments eumelanin (black) or 
pheomelanin (red/yellow) through Mc1r signaling. Agouti binding functions as a 
competitive inhibitor to reduce Mc1r activity, resulting in the production of 
pheomelanin, while activation of Mc1r by α-melanocyte signaling hormone (α-MCH) 
binding causes melanocytes to produce eumalanin (Ollmann et al., 1997; Sakai et 
al., 1997). Both Mrgn1 and Atrn loss of function phenotypes require the presence of 
Mc1r for the expression of eumelanin since Mc1r(-/-) animals are yellow regardless 
of the Mgrn1 or Atrn genotype (Miller et al., 1997). While Mc1r was determined to be 
a substrate for Mgrn1 binding, Mgrn1 does not ubiquitinate Mc1r or melanocortin-4 
receptor (Mc4r), but does ubiquitinate Mc2r, highlighting the specificity of the E3 
ubiquitin ligase activity (Cooray et al., 2011; Perez-Oliva et al., 2009). Perez-Oliva 
and colleagues found that Mgrn1 reduced Mc1r and Mc4r signaling and production 
of cAMP without altering its cell surface expression or rate of turnover by inhibiting 
the interaction of Mc1r and Mc4r with Gα, thus preventing the activation of adenylate 
cyclase. This competitive inhibition of GPCR function without ubiquitination appears 
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to be a novel role for E3 ubiquitin ligases. However, a recent study has shown that 
Mgrn1 controls the sorting of Mc4r to the lysosome for degradation through 
monoubiquitination of tumor susceptibility gene 101 (TSG101) and that knockdown 
of Mgrn1 with siRNA did not restore cAMP levels, thus contradicting the results of 
Perez-Oliva, et al. with regard to Mc4r (Overton and Leibel, 2011). TSG101 is a key 
component of the endosome sorting complex required for trafficking (ESCRT-1) 
pathway that is responsible for trafficking vesicles to the lysosome for degradation 
(Babst et al., 2000). Depletion of Mgrn1 in HeLa cells produced enlarged early and 
late endosomal vesicles, and inhibited the lysosomal degradation of activated 
epidermal growth factor receptor (EGFR) (Kim et al., 2007). Additionally, Mgrn1 may 
play some role in the regulation of metabolism since Mgrn1 loss of function caused 
reduced food intake and subsequent body mass reduction in normally obese Agouti 
overexpressing Yellow mice, and resulted in an 80% reduction in plasma insulin in 
Mc4r null mice (Overton and Leibel, 2011; Phan et al., 2006). Finally, Mgrn1 
knockout pups have altered expression of the patterning genes Nodal1, Lefty1, and 
Lefty2 leading to a high instance of congenital heart defects and greatly decreased 
survivability associated with abnormal L/R patterning (Cota et al., 2006). Clearly, 
Mgrn1 is involved in a diverse and critical number of cellular processes and should 
continue to be the target of dedicated investigation. 
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Mahogunin and TSE 
 
Mgrn1 has emerged as a molecule of marked importance with regard to TSE 
pathogenesis since Mgrn1 knockout mice also display progressive spongiform 
vacuolation of the CNS similar to TSE but without the presence of pathogenic PrPSc 
(He et al., 2003b). Specifically, the non-agouti curly (mdnc/mdnc) mutation of 
Mahogunin caused progressive spongiform changes and degeneration in the 
cerebral cortex, striatum, thalamus, hippocampus, and brain stem, and cerebellum. 
By one year of age, mice had widespread astrogliosis associated with neuronal loss. 
Further studies on the role of Mgrn1 in spongiform degeneration discovered that 
PrPC exposed to the cytosol allosterically inhibits Mgrn1 E3 ubiquitin ligase function 
(Chakrabarti and Hegde, 2009). Therefore, it is possible that the interaction of Mgrn1 
with intercellular PrPSc may be a key contributor to spongiform degeneration 
indicative of TSE. However, recent evidence has indicated that neither 
overexpression nor knockout of Mgrn1 affects the progression of mouse adapted 
scrapie (Silvius et al., 2013). Although Mgrn1 binds with PrPC at the octapeptide 
repeat domain, PrPC is not a substrate for Mgrn1-catalyzed ubiquitination 
(Chakrabarti and Hegde, 2009; He et al., 2003b).  However, since PrPSc 
accumulates in early endosomal vesicles, inhibition of Mgrn1 activity during TSE 
pathogenesis may alter vesicle trafficking and prevent lysosomal degradation of 
PrPSc aggregates. A possible mechanism for the interaction of Mn induced cytosolic 
PrP and Mgrn1 is proposed in research chapter 3.  
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Figure 3 Interaction of PrPC and Mgrn1 
 
Apoptotic cell death in TSE 
 
Activation of caspases and fragmentation of DNA, both hallmarks of apoptotic 
cell death, have been observed in both in vitro and in vivo models of TSE-related 
neurodegeneration (Bourteele et al., 2007; Carimalo et al., 2005; Fairbairn et al., 
1994; Hetz et al., 2003; Offen et al., 2000). Caspase-3 belongs to a highly 
conserved group of cysteine proteases that are central in the execution of PCD in 
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response to apoptotic stimuli. Dependent upon the specific apoptotic stimuli, distinct 
initiator caspases are activated that in turn proteolytically cleave the full length 
procaspase-3 into a catalytically active form. In the extrinsic apoptotic pathway, 
extracellular death signals belonging to the tumor necrosis factor (TNF) family of 
proteins are transduced by TNF receptors which activate initiator caspases 8 and 
10. In the intrinsic pathway, cellular damage by oxidative stress or cytotoxic agents 
causes depolarization of the mitochondrial membrane, release of cytochrome C from 
the mitochondria, and subsequent activation of initiator caspase-9 (Cain et al., 2002; 
Reed, 2004). After prolonged induction of the unfolded protein response during 
endoplasmic reticulum stress, initiator caspase-12 is activated which can lead to 
apoptotic cell death as well (Hetz et al., 2003). However, the apoptotic pathway 
involving ER stress is still under investigation as recent studies have found that ER 
induced PCD can occur independent of caspase-12 activation (Di Sano et al., 2006; 
Obeng and Boise, 2005; Steele et al., 2007).  
A variety of potential apoptotic stimuli have been implicated in TSE related 
apoptosis, including oxidative and endoplasmic reticulum stress (Fairbairn et al., 
1994; Ferreiro et al., 2006; Ferreiro et al., 2008; Hetz et al., 2003; Kim et al., 2001; 
Milhavet and Lehmann, 2002; Soto, 2008). Persistent infection by PrPSc increases 
susceptibility to oxidative stress in neuroblastoma cells (Fernaeus et al., 2005; 
Milhavet et al., 2000). Our group has discovered that expression of PrPC 
exacerbates ER stress-related apoptosis induced by treatment with tunicamysin 
(Anantharam et al., 2008). Despite these discoveries, the signaling cascades leading 
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to prion-induced apoptosis are still unclear. A detailed understanding of the 
molecules involved in prion related cell death would not only expand the 
understanding of a unique neurodegenerative disease, but may also provide 
potential targets for pharmaceutical intervention. 
 
The role of PKCδ in neurodegeneration 
 
 The delta isoform of protein kinase C (PKCδ) is a ubiquitously expressed, 
diacylglycerol (DAG) dependant, calcium independent serine/threonine kinase 
whose normal cellular functions include cellular differentiation, proliferation, 
secretion, and apoptosis (Benes and Soltoff, 2001; Kanthasamy et al., 2003; 
Kikkawa et al., 2002; Miyamoto et al., 2002; Orosco et al., 2006; Reyland, 2007). 
Under a variety of apoptotic stimuli, including agents of oxidative or endoplasmic 
reticulum stress, PKCδ is proteolytically cleaved by the effector caspase, caspase-3, 
into two subunits: regulatory and catalytic (Kanthasamy et al., 2003; Kikkawa et al., 
2002; Kitazawa et al., 2005; Reyland, 2007; Yang et al., 2004). Separation of the 
regulatory domain from the catalytic domain by proteolytic cleavage produces a 
persistently active kinase that translocates to several different cellular organelles, 
including the nucleus, mitochondria, and plasma membrane, and induces apoptotic 
cell death (Kanthasamy et al., 2003; Kikkawa et al., 2002; Reyland, 2007; Yoshida, 
2007). Expression of the catalytic domain alone was shown to be sufficient to induce 
apoptosis in cells (Denning et al., 2002). Inhibition of caspase-3 or PKCδ catalytic 
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activity protects cells from apoptosis induced by oxidative and endoplasmic 
reticulum stress (Anantharam et al., 2004; Choi et al., 2007; Hetz et al., 2003; Kaul 
et al., 2003; Kitazawa et al., 2003; Kitazawa et al., 2004; Latchoumycandane et al., 
2005; Yang et al., 2004). A study done by our lab indicated that inhibition of PKCδ 
activity by rottlerin protects mice treated with theo xidative stress inducing 
Parkinsonian toxin MPTP (Zhang et al., 2007). Animals treated with rottlerin showed 
increased dopamine levels and subsequent locomotor function when compared to 
animals only treated with toxin. This study shows that inhibition of PKCδ 
proapoptotic activity may be a powerful tool in the treatment of neurodegenerative 
disorders. 
 
Figure 4 Progression of Murine RML Scrapie 
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Current and future therapies against prion disease 
   
 To date, there is only a single drug, quinacrine, currently undergoing clinical 
trials to treat TSE. Unfortunately, the vast majority of promising compounds that 
have shown anti-prion activity in in vitro cell culture models fail to show any impact 
on the course of the disease in in vivo animal models or during clinical trials. The 
focus on inhibition of the prion mechanism may be premature since the mechanism 
of this phenomenon is still unknown. Due to the emerging interconnectivity of all 
proteinaceous neurodegenerative disorders, the pathways of neurodegeneration 
elucidated within PD, AD, and ALS models may help to establish new opportunities 
for pharmaceutical intervention in all prion diseases. 
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Abstract 
 
Protein misfolding and aggregation are considered key features of many 
neurodegenerative diseases, but biochemical mechanisms underlying protein 
misfolding and the propagation of protein aggregates are not well understood. 
Prion disease is a classical neurodegenerative disorder resulting from the 
misfolding of endogenously expressed normal cellular prion protein (PrPC).  
Although the exact function of PrPC has not been fully elucidated, studies have 
suggested that it can function as a metal binding protein.  Interestingly, increased 
brain manganese (Mn) levels have been reported in various prion diseases 
indicating divalent metals also may play a role in the disease process.  Recently, 
we reported that PrPC protects against Mn-induced cytotoxicity in a neural cell 
culture model.  To further understand the role of Mn in prion diseases, we 
examined Mn neurotoxicity in an infectious cell culture model of prion disease.  
Our results show CAD5 scrapie-infected cells were more resistant to Mn 
neurotoxicity as compared to uninfected cells (EC50 = 428.8 µM for CAD5 
infected cells vs. 211.6 µM for uninfected cells).  Additionally, treatment with 300 
µM Mn in persistently infected CAD5 cells showed a reduction in mitochondrial 
impairment, caspase-3 activation, and DNA fragmentation when compared to 
uninfected cells.  Scrapie-infected cells also showed significantly reduced Mn 
uptake as measured by inductively coupled plasma-mass spectrometry (ICP-
MS), and altered expression of metal transporting proteins DMT1 and transferrin.  
Together, our data indicate that conversion of PrP to the pathogenic isoform 
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enhances its ability to regulate Mn homeostasis, and suggest that understanding 
the interaction of metals with disease-specific proteins may provide further insight 
to protein aggregation in neurodegenerative diseases.  
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1. Introduction 
 
A conformational isomer of the endogenously expressed prion protein is 
the putative pathogenic agent in transmissible spongiform encephalopathy (TSE) 
or prion disease (Prusiner, 1991) .  Normal cellular prion protein (PrPC) is 
converted to the pathogenic β-sheet-rich conformation of scrapie prion (PrPSc) 
through a still unclear mechanism (Bolton et al., 1985; Collinge, 2005; Prusiner 
and DeArmond, 1990).  Prion diseases are fatal neurodegenerative disorders 
that affect both humans and animals (Prusiner, 1991). The regions of the brain 
that control motor function, including the basal ganglia, cerebral cortex, thalamus, 
brain stem, and cerebellum, are severely affected in TSE. The major neurological 
symptoms of TSE are extrapyramidal motor signs, including tremors, postural 
instability, ataxia, and myoclonus (Aguzzi and Heikenwalder, 2006; Brandner, 
2003; Brown, 2002; Tatzelt and Schatzl, 2007).  The neuropathological 
characterization of prion disease involves massive neuronal degeneration and 
vacuolization associated with accumulation of PrPSc giving neural tissue the 
diagnostic spongiform appearance when examined histologically (Collinge, 2001; 
Owen et al., 1989; Palmer and Collinge, 1992).  Increased oxidative stress 
markers, such as malondialdehyde, 3-nitrotyrosine, 8-hydroxyguanosine, protein 
carbonyls, and dysregulation of iron homeostasis were observed in the brain 
tissues of both animal and human prion diseases, suggesting that oxidative 
damage plays an important role in the pathogenesis of TSE (Freixes et al., 2006; 
Lee et al., 1999; Petersen et al., 2005; Yun et al., 2006).   
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Although normal cellular PrPC is abundantly expressed in the central 
nervous system (CNS), its biological function still remains unclear.  PrPC is a 
glycosylphosphatidylinositol (GPI)-anchored cell surface protein that is believed 
to function as an antioxidant, a cellular adhesion molecule, a signal transducer, 
and a metal binding protein (Brown, 2004; Chen et al., 2003; Chiarini et al., 2002; 
Collinge, 2005; Mange et al., 2002; Prusiner and Kingsbury, 1985; Prusiner et al., 
1990; Sakudo et al., 2004).  Properly folded prion protein is present on lipid 
membrane rafts, and is believed to be internalized via clathrin-mediated 
endocytosis (Nunziante et al., 2003; Peters et al., 2003; Prado et al., 2004).  
Recent evidence indicates that PrPC is an important metal binding protein for 
divalent metals, such as copper (Cu), manganese (Mn), and zinc (Zn) (Brazier et 
al., 2008; Brown, 2009; Choi et al., 2007; Hornshaw et al., 1995; Viles et al., 
1999).  PrPC contains several octapeptide repeat sequences (PHGGSWGQ) 
toward the N-terminus, which have binding affinity for divalent metals with 
preferential binding for Cu (Hornshaw et al., 1995; Viles et al., 1999).  Additional 
higher affinity metal binding sites have been identified at His 95 and 110 (mouse 
numbering) (Jackson et al., 2001; Jones et al., 2004), but the exact role of these 
higher affinity metal binding sites remains elusive.  
 
Interestingly, increased Mn content has been observed in the blood and 
brain of humans infected with Crueztfelt-Jacob Disease (CJD), mice infected with 
scrapie, and cattle infected with bovine spongiform encephalopathy (BSE) 
62 
 
(Hesketh et al., 2008; Hesketh et al., 2007; Thackray et al., 2002; Wong et al., 
2001b).  Additionally, Mn-bound PrPSc can be isolated from both humans and 
animals infected with prion disease.  Despite these findings, the role of Mn in the 
pathogenesis of prion disease is currently unknown.  Recent studies using 
recombinant PrP have shown that Mn can irreversibly displace Cu bound to PrP, 
despite an apparent lower affinity, and this displacement causes conformational 
changes within the protein (Brazier et al., 2008; Zhu et al., 2008). The biological 
consequence of Cu replacement by Mn on the prion protein is yet to be 
established.  Recently, we observed that divalent Mn binds to PrP resulting in a 
reduced neurotoxic response during the early acute phase of the Mn toxicity in 
an uninfected model of prion disease (Choi et al., 2007).  However, prolonged 
exposure to Mn upregulates PrPC by stabilizing the protein without any change in 
gene transcription (Choi et al., 2010).  In order to determine whether Mn plays a 
role in the infectious nature of PrP, in the present study we characterized the 
neurotoxic effect of Mn in a cell culture model of infectious prion disease.   
 
2. Materials and Methods 
 
2.1 Chemicals 
 
Manganese chloride (MnCl2), 3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyltetrazolium 
bromide (MTT), ethylenediaminetetraacetic acid (EDTA), phenylmethylsulfonyl 
fluoride (PMSF), sodium chloride (NaCl), Tris HCl, Triton-X, sodium 
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deoxycholate, dithiothreitol (DTT), proteinase K (PK), were purchased from 
Sigma (St. Louis, MO); Sytox green nucleic dye was purchased from Molecular 
Probes (Eugene, OR). Cell Death Detection ELISA plus Assay Kit was 
purchased from Roche Molecular Biochemicals (Indianapolis, IN). Bradford 
protein assay kit and acrylamide stock solution were purchased from Bio-Rad 
Laboratories (Hercules, CA). Opti-MEM, fetal bovine serum, penicillin, and 
streptomycin were purchased from Invitrogen (Carlsbad, CA). 6H4 anti-PrP 
monoclonal antibody was purchased from Prionics (Schlieren, Switzerland).  
Anti-4-hydroxynonenal (4-HNE) antibody was purchased from R&D Systems 
(Minneapolis, MN).  Anti-mouse divalent metal transporter (DMT-1) was 
purchased from Alpha Diagnostic International (San Antonio, TX).  Anti-mouse 
transferrin (Tf) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  
Anti-β-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO).  Alexa 
Flour 680 conjugated goat anti-mouse IgG was purchased from Invitrogen 
(Carlsbad, CA).  Goat anti-rabbit IgG IR800 Conjugate was purchased from 
Rockland Immunochemicals (Gilbertsville, PA)  
 
2.2 Cell culture model of prion disease  
 
 The CAD-2A2D5 subclone of uninfected and infected Cath.a-differentiated 
cells (CAD5) were a generous gift from Dr. Charles Weissmann of the Scripps 
Institute (Jupiter, FL).  Lack of suitable cell culture models for prion disease has 
hindered in vitro mechanistic investigations over the past few decades.  Recently, 
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Dr. Weissmann’s laboratory has successfully created CAD cells with remarkable 
susceptibility for infection by the Rocky Mountain Lab (RML) mouse scrapie 
strain.  The development and characterization of CAD5 infectious prion cell 
culture model is described elsewhere (Mahal et al., 2007).  Both uninfected and 
RML scrapie-infected cells were grown in Opti-MEM  media supplemented with 
50 units penicillin, 50 µg/ml streptomycin, and 10% qualified fetal bovine serum 
(Invitrogen) and screened for retention of RML scrapie infection in CAD5 cells 
over five subsequent passages. Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37ºC.   
 
2.3 Limited proteolysis  
   
Control and RML-infected CAD5 cells were seeded in a T175 flask and 
allowed to grow to ~90% confluence. Cells were washed once with ice cold 
phosphate buffered saline (PBS) and then lysed in the flask by adding 2 ml of 
lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 5 mM EDTA, 2% Triton X, 
and 2% sodium deoxycholate) and incubated at 4ºC for 30 mins.  Protein 
concentrations were determined by Bradford assay, and 2 mg of protein from 
each sample were brought to equal volume with addition of excess lysis buffer.  
Limited proteolysis was begun by addition of PK to each sample at a 
concentration of 20 µg/ml and incubated at 37°C for 1 h.  Reaction was 
quenched by the addition of 2 mM PMSF (final concentration).  After PK 
digestion, samples were ultracentrifuged at 120,000 X g for 2 h using an Optima 
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Max Ultracentrifuge (Beckman-Coulter, Brea, CA) to pellet the PK-resistant 
fraction.  The supernatant was discarded and 30 µl of PAGE loading buffer and 
DTT was added directly to the pellet.  The samples were then sonicated for 5 
mins in a cup horn sonicator, boiled for 10 mins, and separated by SDS-PAGE 
on a 15% polyacrylamide gel and transferred to nitrocellulose membrane.  The 
membranes were treated with 6H4 anti-PrP monoclonal antibody for 2 h at room 
temperature.  Detection was done with an electrochemiluminescence (ECL) 
detection kit (GE Healthcare, Piscataway, NJ).   
 
2.4 SDS-PAGE and Western blot  
   
Western blot analysis was performed as described previously 
(Anantharam et al., 2002; Kitazawa et al., 2005; Latchoumycandane et al., 2005).  
Following Mn treatment, cells were collected by scraping and washed once with 
ice cold PBS, and then lysed in RIPA (Radio-Immunoprecipitation Assay) buffer 
with phosphatase and protease inhibitor cocktail (Thermo Scientific, Rockfort, IL).  
Protein concentrations of samples were determined using Bradford assay.  
Samples were then separated by SDS-PAGE using a 12% polyacrylamide gel 
and transferred onto nitrocellulose membrane.  After 1 h in blocking buffer, the 
membranes were treated with either anti-4-hydroxynonenal antibody, anti-
transferrin antibody, or anti-divalent metal transporter 1 at 4ºC overnight. 
Membranes were co-treated with anti-β-actin antibody in blocking buffer to 
ensure equal protein loading.  Membranes were then treated with anti-mouse 
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and anti-rabbit fluorescent secondary antibodies for 1 h at room temperature.  
Visualization and band quantification was done using an Odyssey scanner (Licor, 
Lincoln, NE). 
 
2.5 MTT Assay 
 
 The MTT cell viability assay was performed as described previously (Choi 
et al., 2007; Latchoumycandane et al., 2005). 100,000 uninfected and RML 
scrapie-infected CAD5 cells were seeded on a 96-well microplate, allowed to 
adhere for 12 h, and then treated for 16 h with manganese chloride (MnCl2) in 
Opti-MEM in the following concentrations: 0, 10µM, 30µM, 50µM, 100µM, 
300µM, 500µM, 1mM, 2mM, 3mM, and 5mM.  Following the treatment, the cells 
were washed with warm PBS and then incubated with 200 µl 0.25% (w/v) MTT in 
serum free Opti-MEM for 30 mins at 37°C.  MTT treatment was removed, cells 
were washed with warm PBS, and 200 µl of 100% dimethyl sulfoxide (DMSO) 
was added to each well and pipetted up and down to dissolve the contents of the 
wells.  Yellow MTT is reduced by a mitochondrial dehydrogenase in living cells to 
dark blue formazan crystals that accumulate in the mitochondria.  Absorbance 
was read at 570 and 630 nm using a SpectroMax microplate reader (model 190; 
Molecular Devices, Sunnyvale, CA).   
 
2.6 Sytox Staining 
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One million uninfected and RML scrapie-infected CAD5 cells were plated 
in a 6-well plate, allowed to adhere to the plate for 12 h, and then were treated 
with 300 µM and 500 µM MnCl2 in Opti-MEM supplemented with 1 µM Sytox 
green dye for 24 h.  Sytox green is a cell-impermeable nucleic acid dye that 
intercalates with DNA and produces green fluorescence in dead or dying cells.  
Pictures were taken with a Nikon inverted fluorescence microscope (model TE-
2000U; Nikon, Tokyo, Japan); images were captured with a SPOT digital camera 
(Diagnostic Instruments, Sterling Heights, MI.) 
 
2.7 Caspase-3 Time Course  
  
Caspase-3 activity assay was performed as described previously 
(Anantharam et al., 2002; Kitazawa et al., 2005; Latchoumycandane et al., 2005). 
One million uninfected and RML scrapie-infected CAD5 cells were plated per well 
in a 6-well plate, allowed to adhere for 12 h, and were then treated with 300 µM 
MnCl2 in Opti-MEM for 8, 12, 16, 20, and 24 h. Cells were collected with 0.25% 
trypsin-EDTA, spun down at 300 x g for 5 mins, and the cell pellet was washed 
with PBS.  Cells were resuspended in caspase buffer (50 mM Tris-HCl (pH 7.4), 
1 mM EDTA, and 10 mM EGTA) with 10 μM digitonin added and incubated for 30 
mins on ice to lyse cells.  The lysate was quickly spun down and supernatant 
was collected.  95 μl of the lysate was incubated with 5 μl of caspase-3 specific 
substrate Ac-DEVD-AFC for 1 h in a 96-well plate at 37ºC.  AFC fluorescence 
was measured with excitation at 400 nm and emission at 505 nm with a 
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SpectraMax fluorescent plate reader (model GeminiXSE; Molecular Devices, 
Sunnyvale, CA).  Protein concentration was determined by Bradford protein 
assay and data was expressed as fluorescent units per mg of protein per hour. 
 
2.8 DNA fragmentation ELISA on Mn treated CAD5 cells 
 
1 million uninfected and RML scrapie-infected CAD5 cells were plated per 
well in a 6-well plate, allowed to adhere for 12 h, and were then treated with 300 
µM of MnCl2 in Opti-MEM for 24 h.  Cells were collected with 0.25% trypsin-
EDTA and spun down at 300 x g for 5 mins and the cell pellet was washed with 
PBS.  The amount of histone-associated low molecular weight DNA in the 
cytoplasm of the cells was determined with the Cell Death Detection ELISA 
PLUS Kit (Roche, Indianapolis, IN) as described previously (Anantharam et al., 
2002; Choi et al., 2007; Kaul et al., 2003).  Briefly, cells were lysed in provided 
lysis buffer for 30 mins at RT.  Lysate was centrifuged for 10 mins at 200 X g and 
20 μl of supernatant was incubated for 2 h with the mixture of HRP (horseradish 
peroxidase)-conjugated antibodies that recognize histones and single and 
double-stranded DNA.  After washing away the unbound components, the final 
reaction product was measured colorimetrically with 2,2′-azino-di-[3-ethylbenz-
thiazoline sulfonate] as an HRP substrate using a spectrophotometer at 405 nm 
and 490 nm. The difference in absorbance between 405 and 490 nm was used to 
determine the amount of DNA fragmentation in each sample.  All sample 
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concentrations were normalized to protein concentration using the Bradford 
protein assay. 
 
2.9 Determination of intracellular manganese levels by IC-PMS 
 
Three million uninfected and RML scrapie-infected CAD5 cells were 
seeded in a T175, allowed to adhere for 12 h, and then were treated for 16 h with 
300 µM MnCl2 in Opti-MEM media.  Cells were then collected by scraping and 
washed twice with PBS.  Intracellular Mn concentration was measured at m/z 55 
by inductively coupled plasma mass spectrometry (ICP-MS) as described in our 
previous publications (Afeseh Ngwa et al., 2009; Choi et al., 2007).  A magnetic 
sector instrument (ELEMENT 1, Thermo Finnigan) was operated in medium 
resolution (m/Δm = 4,000) to resolve the isotope of interest from possible 
interferences (Shum et al., 1992).  Each sample was placed in an acid-washed 5 
ml Teflon vial and digested in 200 µl triply distilled high purity nitric acid 
(TraceMetal Grade, Fisher Scientific, Pittsburg, PA).  The digested samples were 
then diluted to a final volume of 5 ml with 18.2 MΩ deionized water (Elix and Milli-
Q Gradient, Millipore, Billerica, MA) resulting in a final acid concentration of 4%.  
An internal standard method was used for quantification.  Gallium (Ga) at m/z 69 
was chosen as the internal standard because its m/z ratio is similar to that of Mn, 
and it has no major spectroscopic interferences.  A small spike of Ga standard 
solution was added to each sample for a final Ga concentration of 10 ppb.  A 10 
ppb multi-element standard (Mn and Ga) was prepared. The nitric acid blank, the 
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multi-element standard, and each of the samples were introduced into the ICP-
MS via a 100 µl/min self-aspirating perfluoroalkoxy (PFA) nebulizer (Elemental 
Scientific, Inc., Appleton, WI).  The nitric acid blank was used to rinse the 
nebulizer between each sample.  The results for each sample were calculated 
using the integrated average background-subtracted peak intensities from 70 
consecutive scans.  A normalization factor for Mn was derived from the multi-
element standard to account for differences in the ionization efficiency of each 
element.  The Mn concentration was then calculated for each sample. 
 
2.10 Data Analysis 
 
Statistical analysis was performed with Prism 4.0 software (GraphPad 
Software, San Diego, CA).  Statistical significance among treatments was 
determined by one-way ANOVA analysis with Tukey’s multiple comparison 
testing and is indicated by asterisks with *p<0.05, **p<0.01, and ***p<0.001.  
Analyses between two data sets were done using Student’s t-test.  EC50 values 
were determined by the fitting of a nonlinear regression curve to the data from 
the MTT assay.  Data typically represent three separate experiments and are 
expressed as mean ± S.E.M. 
 
3. Results 
 
3.1 CAD5 characterization and limited proteolysis 
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First, we examined the morphological features and prion infection of CAD5 
cell model used in our experiments. Fig. 1A details the tendency for the RML 
scrapie-infected CAD5 cells to grow as aggregate colonies, while the uninfected 
cells form a more uniform monolayer.  Additionally, the RML scrapie-infected 
cells have an increased doubling time compared to the uninfected cells when 
cultured over several days (data not shown).  We do not see any differences in 
the growth characteristics such as doubling time, morphology, etc. between 
infected and uninfected cells because entire treatment is less than 36 hrs.    
Importantly, the CAD5 strain was able to retain persistent RML scrapie infection 
over multiple passages as determined by limited proteolytic digestion with PK 
and subsequent immunoblot using the 6H4 anti-PrP MAb (Fig. 1B).  An abundant 
proteolytically resistant PrPSc was detected in scrapie-infected cells as compared 
to uninfected cells (Fig. 1B).   
 
3.2 RML scrapie-infected CAD5 cells are more resistant to Mn-induced toxicity 
 
Several lines of evidence from our lab and others have shown that Mn-
induced toxicity in neuronal cell models is associated with mitochondrial 
dysfunction and subsequent generation of reactive oxygen species (ROS) 
leading to cell death (Aschner et al., 2009; Kitazawa et al., 2005; 
Latchoumycandane et al., 2005; Roth et al., 2002; Worley et al., 2002).  In an 
effort to establish a cytotoxic dose of Mn for further cell viability studies in the 
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CAD5 cell culture model of prion disease, both uninfected and RML scrapie-
infected CAD5 cells were exposed to a full dose range of 10-5000 µM  Mn for 16 
h and viability was measured by MTT assay.  As shown in Fig. 2A, a 
concentration-dependent decrease in cell viability for both uninfected and RML 
scrapie-infected cells was observed. A statistically significant difference (p<0.05) 
was observed between the EC50 values for uninfected and RML-infected cells, as 
calculated by a three-parameter nonlinear regression of dose response curves. 
Unexpectedly, the RML scrapie-infected cells showed increased resistance to Mn 
treatment with a calculated EC50 value of 428.8 µM, greater than double the EC50 
value of the uninfected cells, 211.6 µM.  The cytotoxicity results were further 
confirmed by qualitative analysis using Sytox green staining.  Uninfected and 
RML-infected cells were exposed to 300 and 500 µM Mn for 24 h and pictures 
were taken using a Nikon inverted fluorescent microscope. The difference in the 
number of Sytox positive cells is evident at both concentrations of Mn, with 
uninfected CAD5 cells showing a much greater number of Sytox stained cells 
(Fig. 2B).  These studies led us to further examine this disparity in the cytotoxic 
doses of Mn on the uninfected and RML scrapie-infected CAD5 cell line.  Based 
upon these data, we selected 300 µM Mn as an optimal dose for comparative 
studies of Mn-induced cytotoxicity. 
 
3.3 RML scrapie-infected CAD5 cells are more resistant to Mn-induced apoptotic 
cell death 
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Mn-induced neurotoxicity is a known activator of proapoptotic signaling 
cascades in neuronal cells (Aschner et al., 2009; Kitazawa et al., 2005; 
Latchoumycandane et al., 2005; Stredrick et al., 2004).  In order to explore the 
activation of proapoptotic caspases by Mn-induced neurotoxicity in uninfected 
and RML scrapie-infected CAD5 cells, we assayed the activity of the effector 
caspase, caspase-3, at 8, 12, 16, 20, and 24 h treatments with 300 µM of Mn.  At 
24 h treatment, a statistically significant increase in the activation of caspase-3 in 
uninfected cells (p<0.001) was observed, but no such increase was noted in 
RML-infected cells (Fig. 3A).  Furthermore, we quantitatively assessed the level 
of DNA fragmentation on cells treated for 24 h with 300 µM Mn using a Cell 
Death Detection ELISA Kit.  We found a statistically significant increase in the 
level of histone-associated low molecular weight DNA in uninfected cells at this 
time point (p<0.001), while the RML-infected cells showed no significant increase 
(Fig. 3B).  These results indicate that RML scrapie-infected CAD5 cells are more 
resistant to Mn-induced apoptotic cell death than uninfected cells. 
 
3.4 RML scrapie infection attenuates Mn-induced oxidative damage 
 
To further probe the decreased susceptibility of RML-infected CAD5 cells 
to Mn-induced toxicity, we evaluated the incidence of Mn-induced oxidative 
stress by examining a product of lipid peroxidation, 4-hydroxynonenal (4-HNE), in 
Mn-treated CAD5 cells (Alikunju et al., 2011; Sango et al., 2008).  Multiple 
studies have shown that neuronal cell lines persistently infected with PrPSc show 
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increased susceptibility to oxidative stress (Fernaeus et al., 2005; Milhavet et al., 
2000).  As shown in Fig. 4A, uninfected CAD5 cells showed a time-dependent 
increase in the levels of 4-HNE in response to treatment with 300 µM of Mn.  
Surprisingly, scrapie-infected CAD5 cells treated with Mn showed reduced levels 
of 4-HNE when compared to uninfected cells (Fig. 4A). Densitometric analysis 
revealed a statistically significant (p<0.05) decrease in the 4-HNE band intensity 
of RML scrapie-infected cells at 24 h (Fig. 4B). 
 
3.5 RML Infected CAD5 Cells Have Reduced Manganese Accumulation 
 
The binding of divalent cations to PrPC induces clathrin-mediated 
endocytosis of lipid raft domains and this process is dependent upon the metal 
binding sites of PrPC (Brown and Harris, 2003; Hooper et al., 2008; Pauly and 
Harris, 1998; Perera and Hooper, 2001). A recent study from our group showed 
that knockout of PrPC alters Cu and Mn levels in a neuronal cell culture model 
(Choi et al., 2007).  Also, other studies have shown altered divalent metal content 
in the brains of PrPC null and TSE-infected animals.  These results indicate that 
PrPC may have a role in divalent metal homeostasis, and that conversion to the 
disease isoform alters the ability of PrPC to regulate intracellular concentrations.  
In order to examine the consequence of RML scrapie infection on Mn 
homeostasis, we treated uninfected and RML scrapie-infected CAD5 cells with 
300 µM Mn for 16 h and determined the intracellular Mn concentration by 
inductively coupled plasma mass spectrometry (ICP-MS). Uninfected and RML 
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cells had similar basal levels of cytoplasmic Mn; however, Mn treatment 
increased intracellular Mn levels 187-fold in uninfected CAD5 cells and 130-fold 
in RML infected cells (Fig. 5A).  This difference was statistically significant 
p<0.01. 
 
In order to determine a mechanism for the difference in intracellular Mn 
concentration, we assessed the levels of DMT1 and transferrin in control and Mn-
treated CAD5 cells.  As seen in Fig. 5B-C, the basal level of DMT1 was 
increased in RML scrapie-infected CAD5 cells as compared to uninfected cells.  
However, Mn treatment did not cause any significant change in DMT1 levels in 
either cell types (Fig. 5B and 5D).  Also, the basal level of expression of TF in 
uninfected and RML scrapie-infected cells is not significantly different (Fig. 5E-F).  
However, upon Mn treatment, there is a statistically significant, time-dependent 
increase in the level of TF in RML scrapie-infected cells.  There was a slight but 
not significant increase in the levels of TF in uninfected cells at 24 h (Fig. 5E and 
5G).  These results show some differences existing in metal transporter protein 
between uninfected and RML scrapie-infected cells.  However, the altered 
expression of these proteins between the uninfected and infected CAD5 cells are 
contradictory to the expected intracellular Mn concentrations since both DMT1 
and TF are involved in Mn influx yet are increased in the infected cells that have 
a decreased Mn content.  These results indicate that there are other factors 
influencing the intracellular level of Mn.  Altered expression of proteins that are 
involved in Mn efflux may also play role in Mn-homeostasis. The mechanisms of 
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regulation that are affected by conversion from PrPC to PrPSc remain an 
interesting target for further study. 
 
4. Discussion 
 
In this study we have shown that RML scrapie-infected catecholaminergic 
cells are more resistant to Mn-induced neurotoxicity than uninfected cells.  
Consistent with cytotoxicity, caspase-3 activation, DNA fragmentation, and ROS 
generation are attenuated in Mn-treated RML scrapie-infected CAD5 cells.  
Another notable finding of our study was that metal transport proteins DMT and 
transferrin are altered in scrapie-infected cells as compared to uninfected cells. 
To our knowledge, this is the first report demonstrating reduced metal 
neurotoxicity in an infectious model of prion disease. 
 
Our understanding of the role of metals in key neurobiological processes, 
as well as in the pathogenesis of various neurodegenerative diseases, has 
greatly expanded over the last two decades.  Studies overwhelmingly 
demonstrate that metal dyshomeostasis, protein aggregation, and oxidative 
stress are interconnected pathophysiological mechanisms of all 
neurodegenerative diseases associated with proteinopathies.  Significant 
imbalances in major transition metals such as iron, copper, and zinc are 
implicated in other major neurodegenerative conditions such as Parkinson’s 
disease (PD),  Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) and 
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Huntington Disease (HD) (Bishop et al., 2002; Bossy-Wetzel et al., 2004; Brown, 
2009; Bush and Curtain, 2008; Cahill et al., 2009; Gaeta and Hider, 2005; 
Molina-Holgado et al., 2007; Sayre et al., 1999).  Another common pathological 
feature of these neurodegenerative disorders is the aggregation of β-sheet-rich 
synaptic proteins associated with each disease (e.g., α-synuclein in PD, a-beta in 
AD, and huntingtin in HD).  Environmental exposure to transition metals is linked 
to pathological processes of various neurodegenerative conditions since metal 
exposure is known to augment key degenerative changes including ionic 
imbalance, oxidative stress, and protein aggregation (Afeseh Ngwa et al., 2009; 
Anantharam et al., 2002; Aschner et al., 2009; Crossgrove and Zheng, 2004; 
Kitazawa et al., 2001; Park et al., 2005; Wu et al., 2008). 
 
Emerging evidence indicates that dysregulation of divalent cation 
homeostasis may play a role in the pathogenesis of prion diseases (Basu et al., 
2007; Brown, 2009; Choi et al., 2006; Singh et al., 2009).  PrPC contains multiple 
octapeptide repeat sequences (PHGGSWGQ) toward the N-terminus that have 
binding affinity for various divalent metals including copper and manganese 
(Hornshaw et al., 1995; Viles et al., 1999).  The number of octapeptide repeats 
differs from species to species; however, point mutations, deletions or multiple 
insertions of the octapeptide repeats in the prion protein gene have been linked 
to inherited prion disease in humans (Krasemann et al., 1995; Mead et al., 2007; 
Palmer and Collinge, 1993; Yin et al., 2007).  Structural studies have suggested 
that most of the N-terminus of prion protein is rather unstructured, while the C-
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terminus is highly structured (Di Natale et al., 2005; Jones et al., 2005; Renner et 
al., 2004; Viles et al., 2001).  Binding of divalent cations to PrPC has been 
speculated to facilitate the folding of the largely unstructured N-terminus, thereby 
stabilizing the protein conformation (Cereghetti et al., 2003).  The antioxidant 
properties of PrPC have been linked to Cu residency in the octapeptide repeat 
domain (Brown et al., 2001; Brown et al., 1999; Gaggelli et al., 2008; Treiber et 
al., 2007).  Cu bound by PrPC is able to undergo full and reversible redox 
chemistry, allowing for the detoxification of superoxide and the reduction of 
hydroxyl radicals (Nadal et al., 2007).  Recently, we showed that prion protein 
expressing cells are more resistant to oxidative damage as compared to prion 
knockout cells (Anantharam et al., 2008).  
 
Mn is an important trace elemental metal that is required by most 
organisms for normal functioning; however, continued exposure to high 
concentrations of Mn results in adverse neurological deficits commonly referred 
to manganism.  Interestingly, elevated Mn levels have been observed in the brain 
and blood of humans and animals afflicted with prion diseases and Mn-bound 
PrPSc has been isolated from TSE-infected neural tissue (Hesketh et al., 2008; 
Hesketh et al., 2007; Thackray et al., 2002; Wong et al., 2001a).  In vitro titration 
calorimetry studies done using recombinant PrP have shown that Mn can replace 
Cu residency in the metal binding sites despite a calculated lower affinity (Brazier 
et al., 2008; Zhu et al., 2008). Mn binding to PrPC induces biophysical properties 
similar to PrPSc, including increased β-sheet content, proteolytic resistance, and 
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the ability to seed aggregation of soluble oligomers, yet the role of metals in the 
disease is not very well understood (Abdelraheim et al., 2006; Brazier et al., 
2008; Brown et al., 2000; Giese et al., 2004; Kim et al., 2005). Recently, we 
demonstrated that PrPC effectively attenuates Mn transport into neuronal cells 
and protects against Mn-induced oxidative stress, mitochondrial dysfunction, 
cellular antioxidant depletion, and apoptosis (Choi et al., 2007).  In addition, we 
found that Mn treatment upregulates PrPC levels independently of transcription 
(Choi et al., 2010).  Further mechanistic studies revealed that Mn increases 
stability of prion protein, suggesting that Mn may promote the conversion of PrPC 
to PrPSc.    Our present study shows that the scrapie-infected cells are more 
resistant to Mn neurotoxicity and the infected cells have altered metal transport 
as compared to uninfected cells.  Taken together, these results suggest that 
conversion to PrPSc may result in greater affinity for Mn and increased ability for 
PrPSc to sequester and export excess Mn through the exosomal pathway in 
neuronal cells (Fevrier et al., 2005).  Additionally, the resistance of prion-infected 
cells to Mn neurotoxicity may aid the propagation of prion protein aggregation 
from infected cells to healthy cells.  Further studies are on-going in our laboratory 
to address these possibilities.  However, the possibility of other factors such as 
altered expression of Mn efflux proteins or the increase or activation of other 
survival factors influencing Mn toxicity in infected cells cannot be completely 
ruled out.   
In this study we focused on the CAD cell line, which is derived from 
catecholaminergic neurons; whereas in humans and animals with prion disease, 
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higher Mn levels in brain tissue may be attributed to an increase in Mn-levels in 
microglia and astrocytes which constitute at least 90% of the total brain cell 
population.  Consequence of prion infection on glial cells remains an interesting 
area of study.  Unfortunately, the mechanisms involved in the regulation of 
cellular Mn homeostasis are still not well understood.  Influx of Mn across the 
plasma membrane is believed to be mediated by divalent metal transporter 1 
(DMT1) and transferrin (TF), despite dissociation constants in the millimolar 
range (Aschner et al., 1999; Erikson and Aschner, 2006; Fitsanakis et al., 2007; 
Garrick et al., 2006; Yokel, 2009).  It is possible that ferroportin and ion channels 
are involved in Mn efflux (Yin et al., 2010). Increased resistance to oxidative 
stress in RML scrapie-infected cells is not likely to be a contributing factor in 
reducing the Mn toxicity observed in this work since prion infection has been 
shown to increase susceptibility of neuronal cells to oxidative stress (Fernaeus 
and Land, 2005; Fernaeus et al., 2005).  Finally, a large body of evidence 
indicates that presence of dopamine in SH-SY5Y and other dopaminergic cell 
lines may directly influence the degree of Mn toxicity (For review see (Aschner et 
al., 2009; Smargiassi and Mutti, 1999.).  However, in Cath.a cells, suppression of 
dopamine production with alpha-methyl-para-tyrosine offered no significant 
protection from Mn exposure suggesting that dopamine content was not 
responsible for the enhanced sensitivity to Mn toxicity which rules out the 
utilization of Mn as a co-factor (Stredrick et al., 2004).  Further work is clearly 
needed to elucidate the interconnectivity of metal dyshomeostasis and protein 
aggregation in neurodegenerative disorders. 
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Figures 
 
 
Fig. 1. Characterization of CAD5 cells and RML scrapie infection.  A) Phase 
contrast image of uninfected and RML scrapie-infected CAD5 cells.  
Scrapie-infected cells tend to grow in aggregated colonies and grow more 
slowly than uninfected cells.  B) Lysate from uninfected and infected 
CAD5 cells was proteolytically digested by addition of 20 µg/ml PK for 1 h 
at 37ºC.  Immunoblot with anti-PrP MAb showed complete digestion of 
PrPC in uninfected cells, and the presence of proteolytically resistant PrPSc 
in infected cells.  The multiple bands represent the three glycoforms of 
PrP.   
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Fig. 2. RML scrapie-infected CAD5 cells are more resistant to Mn-induced 
toxicity.  A) Uninfected and RML scrapie-infected CAD5 cells were treated 
with 10, 30, 50, 100, 300, 500, 1000, and 5000 µM Mn for 16 h and cell 
viability was measured by MTT assay.  The LD50 value of the control cells 
was determined to be 211.6 µM (95% CI 136.8-304.8 µM, logEC50: -
3.675±0.081) while in RML scrapie infected cells the LD50 was calculated 
to be 428.8 µM (95% CI 290.9-632 µM, logEC50: -3.368±0.086).  RML 
scrapie-infected cells showed reduced susceptibility to Mn-induced toxicity 
as evidenced by the statistically significant (p<0.05) increase in the EC50 
value.  Data shown represent two repeats with a total of 16 individual data 
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points per concentration.  B) Uninfected and RML scrapie-infected CAD5 
cells were treated with 300 µM and 500 µM Mn for 24 h.   Qualitative 
analysis of Mn-induced toxicity was done by Sytox green staining of dead 
and dying cells.  We observed reduced staining by Sytox in RML scrapie-
infected CAD5 cells when compared to uninfected cells. 
 
 
 
Fig. 3. RML scrapie-infected CAD5 cells are more resistant to Mn-induced 
apoptotic cell death.  Uninfected and RML scrapie-infected CAD5 cells 
were treated with 300 µM Mn and the activity of caspase-3 was 
determined by caspase-3 specific fluorogenic substrate over time.  DNA 
fragmentation was assayed after 24 h of Mn treatment by ELISA.  A) 
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Uninfected CAD5 cells showed a time-dependent increase in caspase-3 
activity in response to Mn treatment (p<0.001), while RML scrapie-infected 
CAD5 cells showed no increase at 24 h.  Data shown represents three 
repeats with a total n=7.  B) DNA fragmentation was significantly 
increased (p<0.001) in uninfected cells treated with Mn when compared to 
RML scrapie-infected cells. 
 
 
 
Fig. 4.  RML scrapie infection attenuates Mn-induced ROS generation.    
Uninfected and RML scrapie-infected CAD5 cells were treated with 300 
µM Mn for 16, 20, and 24 h.  A) Generation of Mn-induced ROS was 
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determined by the presence of lipid peroxidation product 4-HNE.  Lysate 
from treated cells was probed after Western blot with anti-4-HNE antibody.  
To ensure equal protein loading, blots were co-treated with β-actin 
antibody.  B) Uninfected CAD5 cells showed a time-dependent increase in 
4-HNE levels as determined by densitometric analysis of three individual 
repeats. A statistically significantly difference in increases of 4-HNE levels 
is seen between uninfected and infected cells at 24 h (p<0.01). 
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Fig. 5. Mn-induced increases in intracellular Mn levels are reduced while the 
levels of metal uptake proteins are increased in RML-infected CAD5 cells.  
A) Uninfected and RML scrapie-infected CAD5 cells were treated with 300 
µM Mn for 16 h and intracellular Mn levels were determined by ICP-MS.  
Basal levels of Mn in uninfected and infected CAD5 cells were not 
significantly different; however, a 187-fold increase was observed in 
uninfected CAD5 cells while RML infected cells saw a 130-fold increase.  
This difference was significantly different with p<0.01.  B-G) The level of 
divalent metal regulator proteins, DMT1 and TF were determined by 
immunoblot.  The basal level of DMT1 (C) was significantly increased in 
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RML scrapie-infected cells (p<0.01), while the basal level of TF (E) was 
unchanged between uninfected and infected cells.  After 16, 20, and 24 h 
of treatment with 300 µM Mn, the level of TF was increased in a time-
dependent manner in RML scrapie-infected cells (p<0.01) (G).  D) The 
level of DMT1 was not significantly increased with Mn treatment.  These 
data represent a mean ± S.E.M. from quantification of three individual 
experiments. 
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Abstract 
 
Despite considerable advances in our understanding of 
neurodegenerative processes associated with prion diseases in the last few 
decades, the cellular mechanisms responsible for the pathology of this 
devastating disease remain unknown. Impairment of the protein quality control 
systems and metal dyshomeostasis have been implicated in the pathogenesis of 
various proteinaceous neurodegenerative disorders. The loss of function of the 
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E3 ubiquitin ligase, Mahogunin RING finger 1 (Mgrn1), in knockout animals 
results in degenerative spongiform pathology within the CNS in the absence of 
pathogenically misfolded prion protein (PrPSc), indicating that impairment of 
Mgrn1 function may be a key determinant of spongiform degeneration observed 
in transmissible spongiform encephalopathy (TSE). Additionally, it has been 
determined that non-pathogenic prion protein (PrPC) ectopically exposed to the 
cytosol is able to allosterically inhibit Mgrn1 E3 ubiquitin ligase function. 
However, the mechanism by which PrPC, a glycophosphotidyl inositol-anchored 
membrane protein, would interact with cytosolically localized Mgrn1 during the 
course of TSE is unknown. In the present study, we report that MnCl2 exposure 
of 200-300 µM results in increased total cytosolic PrP levels in the CAD5 cell 
culture model of murine RML scrapie. Additionally, the cellular distribution of 
PrPC is altered in the motor cortex of mice exposed to 10 mg/kg MnCl2 by oral 
gavage for 10 days. Finally, we report that RML scrapie infection alters 
expression of Mgrn1 in response to MnCl2 treatment independent of transcription 
in CAD5 cells. Since increased Mn has been observed in the brain and blood of 
humans and animals as a result of TSE infection, these findings provide a 
mechanism that integrates metal dyshomeostasis, inhibition of the ubiquitin 
proteasome system, and spongiform neurodegeneration. 
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Introduction 
 
Studies have demonstrated that prion protein undergoes a conversion 
from endogenous membrane-bound protein (PrPC)  to a misfolded transmissible 
neurodegenerative pathogen through changes to its secondary and tertiary 
structure by an as yet unidentified process (Prusiner, 1982). Misfolded prion 
protein (PrPSc) has been identified as the causative agent in transmissible 
spongiform encephalopathy (TSE), yet the various forms of this disease do not 
share a common etiology or pathology (Belay and Schonberger, 2005).   
In most cases of TSE, upon conversion from the normal cellular isoform of 
prion protein (PrPC) to PrPSc, the protein gains resistance to denaturation and 
proteolysis and forms aggregates (Prusiner et al., 1983; Prusiner, 1985 ). In 
some cases of TSE, amyloid plaques composed of PrPSc accumulate in infected 
brain tissue (Bockman et al., 1985; Brown and Gajdusek, 1991; Prusiner et al., 
1983; Prusiner, 1985). Although the etiology and pathogenesis of the various 
neurodegenerative disorders differ, one of the pathological similarities shared 
between all proteinacious neurological diseases is the accumulation of insoluble 
protein aggregates in intra- or extracellular inclusion bodies (Tai and Schuman, 
2008). These inclusions are largely formed by a single protein constituent that is 
associated with the distinct pathology of the underlying disease state (Taylor et 
al., 2002). Disease-associated inclusions are often immunoreactive for ubiquitin, 
indicating that while the proteins constituents are ubiquitinated, they are not 
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degraded by the UPS (Ardley and Robinson, 2004; Kang et al., 2004; Sarge and 
Park-Sarge, 2011). Intracellular protein aggregations have been shown to greatly 
inhibit the UPS, providing a feedback loop that may exacerbate UPS dysfunction 
during disease pathogenesis (Bence et al., 2001; Bennett et al., 2005; Holmberg 
et al., 2004). The E3 ubiquitin ligase mahogunin RING-finger 1 (Mgrn1) has 
emerged as a molecule of marked importance with regard to TSE since Mgrn1 
knockout mice display progressive spongiform degeneration  in the absence of 
PrPSc accumulation (He et al., 2003). Further studies on the role of Mgrn1 in 
spongiform degeneration discovered that prion protein exposed to the cytosol 
allosterically inhibits Mgrn1 E3 ubiquitin ligase function and that this interaction 
may cause the spongiform degeneration indicative of TSE (Chakrabarti and 
Hegde, 2009).  
Although PrPC is highly expressed throughout the CNS, its endogenous 
function remains unknown. Evidence indicates that PrPC may function as an 
antioxidant, a cellular adhesion molecule, a signal transducer, or a metal binding 
protein (Brown, 2004; Chen et al., 2003; Chiarini et al., 2002; Mange et al., 2002; 
Sakudo et al., 2004). While the function of the PrPC is not well defined, the metal 
binding capacity of the protein has been well documented, and is believed to be 
required for its normal function (Brown and Sassoon, 2002; Brown, 2004; Brown, 
2009). Although it is well known that elemental metals are required for normal 
functioning of cells, significant imbalances in major transition metals such as iron 
(Fe), copper (Cu), and zinc (Zn) are implicated in neurodegenerative conditions 
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such as Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral 
sclerosis (ALS) and Huntington disease (HD) (Bishop et al., 2002; Bossy-Wetzel 
et al., 2004; Brown, 2009; Bush and Curtain, 2008; Cahill et al., 2009; Gaeta and 
Hider, 2005; Molina-Holgado et al., 2007; Sayre et al., 1999). Recent discoveries 
have indicated that the pathogenic proteins involved in PD, AD, ALS, and HD 
may have the capacity to transmit the associated disease in a prion-like manner 
(Braak and Del Tredici, 2011; Desplats et al., 2009; Munch et al., 2011; Ren et 
al., 2009). Manganese (Mn) is an essential trace elemental metal that is required 
by organisms for normal functioning; however, continued exposure to high 
concentrations of Mn results in adverse neurological deficits (Aschner, 1999; 
Dobson et al., 2004; Levy and Nassetta, 2003; Pfeifer et al., 2004). Several lines 
of evidence suggest that exposure to Mn or Mn-containing compounds induces a 
variety of cellular changes including mitochondrial dysfunction, increased 
oxidative stress, glutathione depletion, loss of dopaminergic neurons, impairment 
of energy metabolism and antioxidant systems, and alterations in various cell 
signaling pathways (Erikson and Aschner, 2003; Kitazawa et al., 2002; Roth and 
Garrick, 2003). Prolonged exposure to high levels of Mn results in an irreversible 
Parkinson-like condition called manganism (Beuter et al., 1994; Gibbs et al., 
1999; Myers et al., 2003).  
Elevated Mn levels have been observed in both the brain and blood of 
animals and humans infected with TSE (Hesketh et al., 2007; Hesketh et al., 
2008; Thackray et al., 2002; Wong et al., 2001). Additionally, PrPSc bound to Mn 
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has been isolated from both humans and animals  (Thackray et al., 2002; Wong 
et al., 2001). Our group recently discovered that PrPC interacts with Mn to alter 
the metal toxicity, and that Mn exposure increases PrPC levels independent of 
transcription (Choi et al., 2007; Choi et al., 2010; Martin et al., 2011). Despite 
these findings, the role of Mn in the pathogenesis of TSE is currently unknown. 
Studies using recombinant prion protein have shown that, despite an apparent 
lower affinity, Mn can displace Cu and bind to the protein (Brazier et al., 2008; 
Zhu et al., 2008). Recombinant PrPC refolded in the presence of Mn was 
originally thought to bind up to four molecules of Mn at the octapeptide repeat 
domain, similar to Cu (Brown et al., 2000). However, isothermal titration 
calorimetry experiments demonstrated that PrPC binds one molecule of Mn at 
each of two sites (Brazier et al., 2008). The binding of Mn to PrPC was 
irreversible, as was the oxidation of Mn bound to PrPC; however, the biological 
consequence of Mn replacing Cu in PrPC or PrPSc is still unknown. Studies using 
circular dichroism and Raman optical activity indicate that upon PrPC binding to 
Mn, the secondary structure becomes more organized, gaining greater α-helix 
and β-sheet content than Cu-bound PrPC (Brazier et al., 2008; Zhu et al., 2008). 
Limited proteolytic digestion experiments using proteinase K have shown Mn-
bound PrPC gains partial protease resistance, similar to but less profound than 
the diagnostic proteolytic resistance characteristic of PrPSc (Brown et al., 2000; 
Kim et al., 2005). Once bound to Mn, PrPC can also seed polymerization of 
soluble oligomers of metal free PrPC (Abdelraheim et al., 2006; Giese et al., 
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2004). Despite the fact that Mn homeostasis is disrupted during TSE and binding 
of Mn to PrPC induces PrPSc-like biochemical changes within the protein, the role 
of metals in the disease has yet to be established.  
 
Materials and methods 
 
Absolutely RNA Miniprep Kit (Stratagene, La Jolla, CA), RT2 First Strand 
kit (SABiosciences, Frederick, MD), Absolutely RNA Miniprep Kit (Stratagene, La 
Jolla, CA), qPCR primer assay specific for murine Prkcd (SABiosciences, 
Frederick, MD), using a qPCR primer assay specific for murine Mgrn1 
(SABiosciences, Frederick, MD),  
 
Cell culture model of prion disease  
 
The CAD-2A2D5 subclone of uninfected and RML scrapie-infected 
Cath.a-differentiated cells (CAD5) were a generous gift from Dr. Charles 
Weissmann of the Scripps Institute (Jupiter, FL). The isolation and 
characterization of CAD5 prion-infected cell culture model has been previously 
described (Mahal et al., 2007). Uninfected and RML scrapie-infected CAD5 cells 
were grown under identical conditions in Opti-MEM  media supplemented with 50 
units penicillin, 50 µg/ml streptomycin, and 10% qualified fetal bovine serum. The 
propagation of RML scrapie infection was confirmed over five subsequent 
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passages. Cells were maintained at 37ºC in a humidified atmosphere of 5% CO2.  
 
SDS-PAGE and Western blot  
   
Western blot analysis was carried out as previously described 
(Anantharam et al., 2002; Kitazawa et al., 2005; Latchoumycandane et al., 2005). 
Briefly, cells were collected by scraping with a rubber policeman after treatment. 
Protein concentrations were determined by Bradford assay and equal protein 
amounts were then separated by SDS-PAGE using a 15% polyacrylamide gel. 
Samples were then transferred overnight onto nitrocellulose membrane. 
Membranes were blocked for 1 h in blocking buffer, and then treated with SAF32 
anti-PrP monoclonal antibody overnight at 4ºC. Co-treatment with rabbit anti-ß-
actin antibody in blocking buffer was done to ensure equal protein loading. After 
washing, membranes were then treated with anti-mouse and anti-rabbit 
fluorescent secondary antibodies in blocking buffer for 1 h at room temperature. 
Visualization was done using an Odyssey scanner (Licor, Lincoln, NE). Band 
quantification was done using ImageJ software (U.S. National Institutes of 
Health, Bethesda, MD). 
 
Cytosolic and membrane rich fractionation 
 
Cytosolic and membrane fractions were separated by first allowing the 
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cells to swell by incubation on ice in hypotonic homogenization buffer (20mM 
Tris-HCl, 10mM EGTA, 2mM EDTA, 2mM DTT, with protease and phosphatase 
inhibitor cocktail). Cells were then lysed by shearing the cell membranes by 
passage through progressively smaller gauge needles. Sheared lysates were 
then subjected to ultracentrifugation at 100,000 x g for 30 mins to pellet the 
membrane fraction while the cytosolic fraction remained in the supernatant. The 
membrane pellet was rehomogenized by addition of 0.5% Triton X-100 and 0.5% 
sodium deoxycholate and sonication in a cup horn sonicator.  
 
Immunohistochemistry 
 
Mice were treated with 10 mg/kg of Mn in ddH2O by oral gavage for 10 
days. At the conclusion of the treatment, mice were perfused with 4% PFA and 
frozen sections were cut using a cryostat. Coronal sections corresponding to the 
location of the motor cortex and caudate putamen were then treated with SAF32 
anti-PrP antibody (red), anti-Mgrn1 antibody (green) and Hoescht to stain nuclei 
(blue). Pictures were taken with a Nikon inverted fluorescence microscope 
(model TE-2000U; Nikon, Tokyo, Japan); images were captured with a SPOT 
digital camera (Diagnostic Instruments, Sterling Heights, MI). 
 
Quantative real time polymerase chain reaction (qRT-PCR) 
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Total RNA was isolated from uninfected and scrapie-infected CAD5 cells 
treated with 300 µM MnCl2 for 20 h using an Absolutely RNA Miniprep Kit. 
Reverse transcription into first strand complimentary DNA was done using a RT2 
First Strand kit. Total RNA was isolated from Mn-treated mice using an 
Absolutely RNA Miniprep Kit. Reverse transcription into first strand 
complimentary DNA was done using a RT2 First Strand kit. Quantitative PCR 
was done with a MX3000P RT-PCR thermocycler (Stratagene, La Jolla, CA) 
using a qPCR primer assay specific for murine Prkcd. Amplification was 
performed over 40 cycles and quantified as fold increase calculated by 2^∆∆Ct 
(∆∆Ct  = ∆Ct (Mn) - ∆Ct (Con) ) as recommended by the manufacturer.  18S RNA 
was used as a loading control to ensure equal RNA levels per well. Quantitative 
PCR was done with a MX3000P RT-PCR thermocycler (Stratagene, La Jolla, 
CA) using a qPCR primer assay specific for murine Mgrn1. Amplification was 
performed over 40 cycles and quantified as fold increase calculated by 2^-∆∆Ct 
(∆∆Ct  = ∆Ct (Mn) - ∆Ct (Con) ) as recommended by the manufacturer.  18S RNA 
was used as a loading control to ensure equal RNA levels per well.   
 
Data Analysis 
 
Statistical analysis was performed with Prism 4.0 software (GraphPad 
Software, San Diego, CA). Statistical significance among treatments was 
determined by one-way ANOVA analysis with Tukey’s multiple comparison 
113 
 
testing and is indicated by asterisks with @p<0.1, *p<0.05, **p<0.01, and 
***p<0.001. Analyses between two data sets were done using Student’s t-test. 
Data typically represent three separate experiments and are expressed as mean 
± S.E.M. 
 
Results 
 
Mn treatment induces increased cytosolic PrP in a cell culture model of prion 
disease 
 
Our group has reported that Mn treatment induces increased cytosolic 
levels of PrPC in in vitro neuronal cell culture (Choi et al., 2010). In the same 
study we showed that Mn treatment increased PrPC levels in CAD5 cells infected 
with mouse adapted scrapie. In order to determine the consequence of Mn 
treatment on the localization of PrPC in the CAD5 cell culture model of TSE, we 
did subcellular separation of the cytosolic and membrane fractions of Mn-treated 
uninfected and scrapie-infected CAD5 cells. Cells were treated with 300 µM 
MnCl2 in Opti-MEM for 16, 20, and 24 h. After treatment, cytosolic and 
membrane fractions were separated and both fractions were analyzed by 
immunobot analysis using SAF32 anti-PrP antibodies to determine if PrPC was 
present in the cytosol. The protein level loaded for the cytosolic fraction was 
twice that of the membrane fraction. As seen in Figure 1, the level of PrPC is 
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increased in the membrane and cytosolic fractions of both uninfected and RML 
scrapie-infected cells up to 24 h. The levels of PrPSc may be likewise increased 
in RML scrapie-infected cells, but the anti-PrP antibody used does not 
discriminate between isoforms. 
Densitometric analysis of the cytosolic PrPC band in Fig. 1A revealed that 
Mn-exposure induced a statistically significant increase in PrPC levels in both 
uninfected and RML-infected CAD5 cells.  The PrPC levels increased in a time-
dependent manner up to 20 h and then decreased marginally at 24 h; therefore, 
the 20 h time point was used for subsequent experiments.  Further, the extent of 
the increase in PrPC levels in Mn-treated uninfected cells was significantly higher 
compared to Mn-treated RML-infected cells.   
 
Subcellular localization of prion protein in Mn-treated CAD5 cells 
 
In order to visualize the localization of PrPC in the cytosol, 
immunocytochemical analysis was done on Mn treated uninfected and scrapie-
infected CAD5 cells. Cells were treated with 300 µM MnCl2 for 20 h in Opti-MEM 
and then fixed with 4% paraformaldehyde. Cells were then treated with SAF32 
anti-PrP, and anti-Mgrn1 primary antibodies. Imaging was done on an Olympus 
FV1000 confocal microscope (Olympus America Inc., Center Valley, PA). As 
seen in Figure 2, PrPC aggregates within the cytosol of cells that express Mgrn1 
after Mn treatment in both uninfected (Fig. 2A) and RML scrapie-infected (Fig. 
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2B) CAD5 cells. In infected cells, PrPC or PrPSc within the cytosol appears to 
colocalize with Mgrn1 (white arrowheads). The low level of cytosolic PrPC that 
can be seen adjacent to the nucleus in control untreated CAD5 cells most likely 
represents newly synthesized PrPC undergoing processing within the 
endoplasmic reticulum and Golgi apparatus en route to the plasma membrane. 
 
Mn treatment induces increased cytosolic PrPC and colocalization with Mgrn1 in 
an animal model of Mn toxicity 
 
PrPC is normally attached to the exterior of the plasma membrane by a 
GPI anchor and is associated with lipid rafts (Baron et al., 2002; Stahl et al., 
1987). Interestingly, a small number of neuronal cells were found in the 
hippocampus, neocortex, and thalamus that have strong staining for PrPC in the 
cytosol (Mironov et al., 2003). In that study, the cells did not show markers of 
necrosis or apoptosis, and the GPI anchor machinery functioned normally. To 
examine the consequence of Mn treatment on PrPC levels in an in vivo mouse 
model system,  
 
we found a large amount of cells staining positively for PrPC within the cell 
body in the motor cortex (Figure 3) and to a lesser extent in the lateral septal 
nucleus (not shown) when compared to control. Both of these brain regions 
undergo marked neuronal loss and spongiform vacuolation during the course of 
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experimental scrapie in mice, indicating that increased cytosolic PrPC or PrPSc 
levels may play a role in neuronal loss associated with TSE (Fraser and 
Dickinson, 1968; Fraser and Dickinson, 1973; Jesionek-Kupnicka et al., 1999; 
Jesionek-Kupnicka et al., 2001).  
 
mice were treated with 10 mg/kg of Mn in ddH2O by oral gavage once 
daily for 10 days. At the conclusion of the treatment, mice were perfused with 4% 
PFA and frozen sections were cut using a CM1800 cryostat (Leica Biosystems, 
Nussloch, Germany). Coronal sections corresponding to the location of the motor 
cortex were labeled with SAF32 anti-PrP antibody (red), anti-Mgrn1 antibody 
(green) and/or Hoescht nuclear stain (blue). Figure 3 shows PrPC localization 
(red) in the motor cortex of vehicle control and Mn-treated mice at 15X 
magnification. Inset composite images at 90X magnification illustrate cellular 
redistribution of PrPC within the cell body as a result of Mn treatment (inset, white 
arrowheads). In terms of brain regions, we found a large amount of cells staining 
positively for PrPC within the motor cortex (Figure 3) and to a lesser extent in the 
lateral septal nucleus (not shown) when compared to vehicle control. Figure 4 
includes co-labeling of PrPC and Mgrn1 within the motor cortex. Colocalization of 
Mgrn1 (green) and PrPC (red) can be seen in the cytosolic region of multiple cells 
in Mn-treated animals, but not in those treated with just vehicle (white 
arrowheads). Similar to untreated CAD5 cells, vehicle control animals have low 
levels of PrPC staining within the cell body that may correspond to newly 
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expressed PrPC undergoing processing in the endoplasmic reticulum and Golgi 
apparatus for eventual localization in the cell membrane.  
 
Infectious prion protein alters Mgrn1 response to Mn treatment 
  
Although the inhibition of Mgrn1 function by cytosolic PrPC has been 
established (Chakrabarti and Hegde, 2009), the contribution of Mgrn1 to TSE-
related spongiform degeneration has not.  In order to evaluate the effect Mn 
treatment has on the expression of Mgrn1 in a cell culture model of prion 
disease, we did immunoblot analysis on uninfected and RML scrapie infected 
CAD5 cells treated with 300 µM MnCl2 in Opti-MEM for 16, 20, and 24 h (Figure 
5A). Densitometric analysis of the Mgrn1 band in Fig 5A revealed that in 
uninfected cells, Mn treatment induced a time dependent increase in the 
expression of Mgrn1, whereas Mgrn1 levels in scrapie-infected cells did not 
increase with Mn treatment at any time point (Figure 5B).  
 
Transcriptional regulation of Mgrn1 is altered in Mn treated CAD5 cells 
 
We have previously shown that although PrPC is increased in Mn-treated 
cells, the increase is not due to transcriptional upregulation (Choi et al., 2010). In 
order to confirm these results in a cell culture model of prion disease, we 
evaluated the level of PrPC mRNA in CAD5 cells treated with 300 µM MnCl2 for 
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20 h by quantitative real time polymerase chain reaction (qRT-PCR). Although an 
increase in Mgrn1 protein level is apparent in uninfected cells, there is no 
corresponding increase in mRNA (Figure 6). Conversely, while there is no 
increase in Mgrn1 protein level in infected cells, there is a twofold increase in 
Mgrn1 mRNA. These results indicate that the increase in Mgrn1 levels in in 
uninfected cells in response to Mn treatment are not due to transcriptional 
changes, and Mgrn1 levels do not increase in RML scrapie infected cells despite 
an upregulation of Mgrn1 mRNA. 
 
Discussion 
 
Inhibition of protein quality control systems, protein aggregation, and metal 
dyshomeostasis have all been observed in various models of a variety of 
neurodegenerative diseases, yet how these processes interact during disease 
pathogenesis is not well understood  (Lee et al., 2011; Tyedmers et al., 2010). 
Increases in the level of Mn in the brain and blood of both humans and animals 
infected with TSE have led to the speculation that Mn may play a role in TSE 
pathogenesis (Hesketh et al., 2007; Hesketh et al., 2008; Thackray et al., 2002; 
Wong et al., 2001). In the present study we have found Mn exposure induces an 
increase in cytosolic PrP in a cell culture model of TSE and an animal model of 
Mn toxicity. An increase in cytosolic PrPC would act to attenuate Mgrn1 function 
since the N-terminus of PrPC has been shown to bind to Mgrn1 and allosterically 
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inhibit E3 ubiquitin ligase activity, and may contribute to spongiform 
neurodegeneration (Chakrabarti and Hegde, 2009; He et al., 2003). However, a 
recent study found that neither overexpression nor knockout of Mgrn1 altered the 
progression of mouse adapted scrapie indicating that Mgrn1  (Silvius et al., 
2013). Truncation studies identified the octapeptide repeat domain as the 
interaction site of PrPC and Mgrn1 (Chakrabarti and Hegde, 2009). The N-
terminal octapeptide repeat sequences of PrPC (PHGGG/SWGQ) bind divalent 
metals such as copper, manganese, and zinc, with the highest affinity being for 
copper (Hornshaw et al., 1995; Viles et al., 1999). Point mutations, deletions, or 
duplications of the octapeptide repeats in the prion protein gene have been 
linked to inherited TSE in humans and animals (Krasemann et al., 1995; Mead et 
al., 2007; Palmer and Collinge, 1993; Yin et al., 2007). Cu bound by octapeptide 
repeat domain of PrPC is able to undergo reversible redox chemistry allowing for 
antioxidant-like activity (Brown et al., 1999; Brown et al., 2001; Gaggelli et al., 
2008; Nadal et al., 2007; Treiber et al., 2007). An additional higher affinity metal 
binding site has been identified at His 95 and 110 (mouse numbering) (Jackson 
et al., 2001; Jones et al., 2004). This region was named the “5th site” since the 
octapeptide repeat domain accounts for only four of the five Cu molecules bound 
by PrPC (Brazier et al., 2008; Treiber et al., 2007). Interestingly, mutation of the 
histidine residues in this region to isoleucine induces a pathogenic 
transmembrane form of prion protein that has been shown to interact with Mgrn1 
(Chakrabarti and Hegde, 2009). Further studies are required to elucidate the role 
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each metal binding site has in the pathogenesis of TSE. 
The affinity of PrPC for metals is highly dependent upon pH, suggesting a 
mechanism by which PrPC can alter the homeostasis of divalent metals in the cell 
by endocytosis from the cell surface to early endocytotic vesicles with low pH 
where the metal is released, then cycling back to the cell surface (Brown and 
Harris, 2003; Burns et al., 2002). Studies have shown both Cu and Zn exposure 
can induce internalization of PrPC by endocytosis and that this metal induced 
endocytosis is dependent upon the presence of the octapeptide repeats (Pauly 
and Harris, 1998; Perera and Hooper, 2001). Internalized PrPC is either cycled 
back to the plasma membrane or rapidly degraded by the ubiquitin proteasomal 
(UPS) or lysosomal systems (Ciechanover and Brundin, 2003; Kang et al., 2004; 
Laszlo et al., 1992). These prior studies indicated that Mn did not have the same 
internalizing effect as Cu and Zn. However, our group recently reported that Mn 
treatment increases PrPC levels in neuronal cells independent of transcription 
(Choi et al., 2010). Furthermore, we found Mn treatment significantly altered the 
stability of PrPC, suggesting that Mn directly interacts with PrPC.  
Although we have established that scrapie infection alone does not 
change the expression level of Mgrn1 in a cell culture model of TSE, we have 
discovered that uninfected cells have a time dependent increase in Mgrn1 in 
response to Mn treatment while cells infected with scrapie do not. The lack of 
transcriptional upregulation coincident with the increase in Mgrn1 protein levels 
indicates that Mn increases the protein stability or impairs degradation of the 
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protein; however, mRNA levels may be altered at earlier time points and a 
broader mechanistic study is warranted. The fact that the presence of PrPSc 
abrogates the increase in Mrgn1 protein levels, despite an apparent upregulation 
in the message, may indicate a multilevel inhibition of Mgrn1 function through 
modulation of its expression as well as direct allosteric inhibition in response to 
Mn toxicity.  Since Mn is increased during the course of TSE, our results indicate 
that metal dyshomeostasis and impairment of protein degradation are 
interconnected mechanisms in spongiform disease. 
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Figures
 
Figure 1. Manganese induces an increase in cytosolic PrP. Uninfected and 
RML scrapie-infected CAD5 cells were treated with 300 µM MnCl2 for 16, 20, and 
24 h and subcellular fractionation was done to isolate cytocolic and membrane 
rich fractions. The level of PrPC in each fraction was assayed by immunoblot 
using SAF32 anti-PrP antibody. A) Mn treatment induces an increase in cytosolic 
and membrane rich fractions in both uninfected and infected CAD5 cells. B) 
Quantification of cytosolic bands. Levels indicate total PrP since SAF32 does not 
discriminate between PrP isoforms. Membranes were cotreated with anti-ß-actin 
antibody to ensure equal protein loading. Asterisks represent * p<0.05, ** p<0.01, 
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and *** p<0.001 compared to control untreated cells. Data represent mean 
percent control untreated cells ± SEM from four individual experiments. 
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Figure 2. Cytosolic PrP colocalizes with Mgrn1 in Mn treated CAD5 cells. 
Uninfected and RML scrapie-infected CAD5 cells were treated with 200 µM 
MnCl2 for 24 h and fixed with 4% paraformaldehyde. Cells were 
immunohistochemically labeled with SAF32 anti-PrP and anti-Mgrn1 antibodies 
and examined by fluorescent microscopy. A) In untreated uninfected CAD5 cells, 
PrPC (red) localizes to the plasma membrane, while Mgrn1 (green) is 
cytosolically localized. Treatment with Mn induces internal punctate localization 
of PrPC. B) In untreated RML scrapie-infected CAD5 cells, PrP distribution 
appears more condensed, but remains at the cell periphery. Mn treatment 
induces increased internal PrPC and/or PrPSc levels that colocalize with Mrgn1 
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(white arrowheads). Cells were costained with Hoechst nuclear stain to visualize 
nuclei (blue). 
 
Figure 3. Mn treatment induces cytosolically localized PrP in C57 mouse 
motor cortex. Mice were treated for 10 days with 10 mg/kg of Mn by oral 
gavage. Control animals were treated with ddH2O vehicle. Animals were 
perfused with 4% paraformaldehyde, brains were removed and cut in 30 µm 
frozen sections with a cryostat, and immunohistochemically labeled with SAF32 
anti-PrP antibody. In the motor cortex of Mn treated animals, cells with neuronal 
morphology appear to have a large redistribution of PrPC (red) internally within 
the cytosol (white arrowheads, inset). Cells were costained with Hoechst nuclear 
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stain to visualize nuclei (blue). This pattern of redistribution appeared in the 
lateral septal nucleus as well (data not shown).  
 
Figure 4. Cytosolic PrP and Mgrn1 colocalize in the motor cortex of Mn 
treated mice. Mice were treated for 10 days with 10 mg/kg of Mn by oral gavage. 
Control animals were treated with ddH2O vehicle. Animals were perfused with 4% 
paraformaldehyde and brains were cryosectioned. Immunohistochemical labeling 
with SAF32 anti-PrP antibody and Mgrn1 show colocalization of cytosolic PrPC 
(red) and Mgrn1 (green) in mouse motor cortex of Mn treated animals. Cells were 
costained with Hoechst nuclear stain to visualize nuclei (blue). 
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Figure 5. RML scrapie-infected CAD5 cells have altered Mgrn1 levels in 
response to Mn treatment. Uninfected and RML scrapie-infected cells were 
treated with 300 µM MnCl2 for 16, 20, and 24 hours. Cell lysate was analyzed by 
SDS-PAGE and immunoblotting with anti-Mgrn1 antibody. A) Uninfected cells 
displayed a significant increase in Mgrn1 protein levels with Mn treatment at 20 
and 24 hours while Mgrn1 levels in RML scrapie-infected cells remained 
unchanged. B) Densitometric analysis of Mgrn1 protein levels in uninfected and 
RML scrapie infected cells. Membranes were colabeled with anti-ß-actin antibody 
and Mgrn1 values were normalized to ß-actin levels to ensure equal protein 
concentrations. Asterisks represent * p<0.05 and ** p<0.01. Data represent mean 
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± SEM from three individual experiments. 
 
Figure 6. Transcriptional regulation of Mgrn1 is altered in RML scrapie-
infected CAD5 cells. Uninfected and RML scrapie-infected cells were treated 
with 300 µM MnCl2 for 20 hours and total RNA was isolated. RNA was quantified 
by NanoDrop and RNA levels were equalized. Reverse transcription was done to 
produce cDNA and the level of Mgrn1 was assayed by SYBR-green real time 
quantitative PCR analysis. Despite an increase in Mgrn1 protein levels, Mgrn1 
mRNA is unchanged in uninfected CAD5 cells. However, in RML scrapie-infected 
cells, Mgrn1 gene transcription is slightly but significantly upregulated. Asterisks 
represent ** p<0.01. Data represent mean ± SEM from three individual 
experiments each with two replicates. 
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Abstract 
 
An abnormal isoform of the endogenous prion protein is the putative 
pathogenic agent of transmissible spongiform encephalopathy (TSE). TSE is 
characterized by extensive gliosis, neuronal loss, and spongiform vacuolization in 
the central nervous system of infected humans and animals. Despite considerable 
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effort, the process of conversion from the normal cellular isoform (PrPC) to the 
pathogenic conformation (PrPSc), as well as the endogenous function of PrPC have 
yet to be deciphered. Biochemical signs in the CNS of TSE-infected organisms 
include accumulation of protease resistant PrPSc, neuronal loss, oxidative stress, 
DNA fragmentation, and caspase-3 activation implicating apoptotic cell death as the 
probable cause of neuronal loss observed in TSEs. In order to design effective 
treatments for TSE, the molecules involved in TSE-related neuronal apoptosis must 
be more clearly understood. Our lab has extensively characterized the proteolytic 
activation of a novel protein kinase C, PKCδ, in the pathogenic apoptotic cell death 
of dopaminergic neuronal cells in Parkinson’s disease. Therefore, in this study, we 
characterized the role of PKCδ in neuronal apoptosis associated with TSE. Our 
results have identified constitutive activation of PKCδ by cleavage in multiple brain 
regions in a mouse-adapted scrapie model. We also report changes in the 
phosphorylation of PKCδ at two regulatory sites: T505 within the activation loop of 
PKCδ to evaluate activation of native kinase activity and Y311 which flanks the 
caspase-3 cleavage site of PKCδ and precedes proteolytic activation. Additionally, 
we have discovered that PKCδ knockout animals display a significant delay in the 
onset of motor symptoms associated with TSE and have an altered pattern of 
oxidative damage and neuronal degeneration. These data indicate that PKCδ 
signaling may contribute to neurodegeneration observed during the course of TSE.  
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Introduction 
 
The prion protein undergoes a conversion from endogenous membrane 
bound protein (PrPC) to transmissible neurodegenerative pathogen (PrPSc) through 
changes in its secondary and tertiary structure by an as yet unidentified process 
(Chatigny and Prusiner, 1980; Prusiner, 1982). Misfolded prion protein has been 
identified as the sole causative agent in transmissible spongiform encephalopathy 
(TSE), yet these diseases do not share a common etiology or pathology. A variety of 
potential apoptotic stimuli have been implicated in TSE related apoptosis, including 
oxidative and endoplasmic reticulum stress (Fairbairn et al., 1994; Ferreiro et al., 
2006; Ferreiro et al., 2008; Hetz et al., 2003; Kim and Smith, 2001; Milhavet and 
Lehmann, 2002; Soto, 2008). Several hallmarks of apoptotic cell death have been 
observed in relation to TSE-related neurodegeneration in both in vitro and in vivo 
models, including caspase activation and DNA fragmentation (Bourteele et al., 2007; 
Fairbairn et al., 1994; Hetz et al., 2003; Offen et al., 2000). Additionally, our group 
has discovered that expression of PrPC exacerbates apoptosis induced by the ER 
stress-inducing agent tunicamysin (Anantharam et al., 2008). Despite these 
discoveries, the signaling cascades leading to prion-induced apoptosis are still 
unclear. 
The delta isoform of protein kinase C (PKCδ) has emerged as a molecule of 
diverse function and marked importance. The normal cellular functions of this 
ubiquitously expressed, diacylglycerol (DAG) dependent, calcium independent 
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serine/threonine kinase include cellular differentiation, proliferation, secretion, and 
apoptosis (Benes and Soltoff, 2001; Kanthasamy et al., 2003; Kikkawa et al., 2002; 
Miyamoto et al., 2002; Orosco et al., 2006; Reyland, 2007). Under a variety of 
apoptotic stimuli, most notably agents of oxidative or endoplasmic reticulum stress, 
PKCδ is proteolytically cleaved by the effector caspase, caspase-3, into two 
subunits: regulatory and catalytic (Kanthasamy et al., 2003; Kikkawa et al., 2002; 
Kitazawa et al., 2005; Reyland, 2007; Yang et al., 2004). Separation of the 
regulatory domain from the catalytic domain produces a persistently active kinase 
that translocates to several different cellular organelles, including the cell membrane, 
nucleus, and mitochondria, and induces apoptosis (Kanthasamy et al., 2003; 
Kikkawa et al., 2002; Reyland, 2007; Yoshida, 2007). Indeed, expression of the 
catalytic domain alone is sufficient to induce apoptosis in cells (Denning et al., 
2002). Inhibition of caspase-3 or PKCδ activity protects cells from both oxidative and 
endoplasmic reticulum stress-related apoptosis (Anantharam et al., 2004; Choi et al., 
2007; Hetz et al., 2003; Kaul et al., 2003; Kitazawa et al., 2003; Kitazawa et al., 
2004; Latchoumycandane et al., 2005; Yang et al., 2004). PKCδ activity is regulated 
by multiple internal phosphorylation sites. Phosphorylation of the tyrosine at site 311 
which flanks the caspase-3 cleavage site has been implicated in the proteolytic 
activation of PKCδ (Kaul et al., 2005; Konishi et al., 1997; Rybin et al., 2004; 
Saminathan et al., 2011). Conversely, an increase in native full length activity or low 
levels of proteolytic activation of PKCδ have been shown to exert an antiapoptotic 
effect (Asaithambi et al., 2011; Brodie and Blumberg, 2003; McCracken et al., 2003). 
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Phosphorylation of T505 in the activation loop of PKCδ has been associated with an 
increase in native kinase activity and pro-survival signaling (Orosco et al., 2006). 
 
Materials and methods 
 
Chemicals and antibodies 
 
PKCδ polyclonal antibody (Santa Cruz cat# sc-213), anti-p-T507 PKCδ 
antibody (Santa Cruz cat# sc-11770), anti-p-Y311 PKCδ antibody (Santa Cruz cat# 
sc-18364-R), anti-caspase-3 antibody (Santa Cruz cat# sc-22140), anti-4-
hydroxynonenal (R&D Systems, Minneapolis, MN), 6H4 anti-PrP antibody (Prionics, 
Schlieren, Switzerland), Fluorojade C (Millipore, Bilerica, MA), Absolutely RNA 
Miniprep Kit (Stratagene, La Jolla, CA), RT2 First Strand kit (SABiosciences, 
Frederick, MD), Absolutely RNA Miniprep Kit (Stratagene, La Jolla, CA), qPCR 
primer assay specific for murine PKCδ (SABiosciences, Frederick, MD), 
electrochemiluminescence (ECL) detection kit (GE Healthcare, Piscataway, NJ). 
 
Mouse models of murine scrapie 
 
The animals and protocol procedures were approved and supervised by the 
Committee on Animal Care (COAC) at Iowa State University. C57Bl/6 and PKCδ(-/-) 
mice at postnatal week 6-8 were arranged by weight and randomized into 8 groups 
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(four mock and four scrapie inoculations ending at 60, 90, 120, and 150 DPI). PKCδ 
knockout animals were kindly provided by Dr. Keiichi Nakayama’s Laboratory, 
Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan (Miyamoto et 
al., 2002). The rationale for time points selected in the study were to determine the 
effect of PKCδ on TSE progression ranging from early stages of the disease prior to 
the onset of motor symptoms to the terminal stage. Infection with the RML strain of 
mouse adapted scrapie protein results in severe clinical presentation within 150-160 
days. Brain homogenate from RML infected mice was generously provided by Dr. 
Juergen Richt, Kansas State University, Manhattan, KS. RML infection was 
performed by intracerebrally injecting 30 µl of 1% (w/v) RML infected brain 
homogenate in PBS. Mock control inoculations were done with 30 µl of 1% 
uninfected brain homogenate. At 60, 90, 120 and 150 DPI WT and PKCδ(-/-) mice 
used in the behavioral experiments were humanely sacrificed and the following brain 
regions were harvested: motor cortex, striatum, thalamus, pons, medulla oblongata, 
and cerebellum. The tissues were dissected out and frozen immediately at -80ºC for 
biochemical evaluation.  
 
SDS-PAGE and Western blot  
   
Western blot analysis was performed as described previously (Anantharam et 
al., 2002; Kitazawa et al., 2005; Latchoumycandane et al., 2005). Following Mn 
treatment, cells were collected by scraping with a rubber scraper, washed once with 
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ice cold PBS, and then lysed in RIPA (Radio-Immunoprecipitation Assay) buffer with 
phosphatase and protease inhibitor cocktail. Protein concentrations of samples were 
determined using Bradford assay and samples were then separated by SDS-PAGE 
using a 10-15% polyacrylamide gel and transferred onto nitrocellulose membrane. 
After 1 h in blocking buffer, the membranes were treated with either anti-PKCδ, anti-
caspase-3, or anti-4-hydroxynonenal at 4ºC overnight. Membranes were co-treated 
with anti-ß-actin antibody in blocking buffer to ensure equal protein loading. 
Membranes were then treated with anti-mouse, anti-goat, or anti-rabbit fluorescent 
secondary antibodies for 1 h at room temperature. Visualization was done using an 
Odyssey scanner (Licor, Lincoln, NE). Image analysis and band quantification was 
doing with ImageJ (NIH, Bethesda, MD). 
 
Limited proteolysis 
 
Dissected rain regions from mock infected and RML scrapie-infected mice 
were homogenized with a pellet pestle in lysis buffer (150 mM NaCl, 50 mM Tris-HCl 
pH 7.4, 5 mM EDTA, 2% Triton X, and 2% sodium deoxycholate). Lysate was 
sonicated for 5 mins in a cup horn sonicator and incubated at 4ºC for 20 mins. 
Protein concentrations were determined by Bradford assay, and 2 mg of protein from 
each sample were brought to equal volume with addition of excess lysis buffer. 
Limited proteolysis was begun by addition of 20 µg/ml PK to each sample and 
incubated at 37°C for 1 h. Reaction was quenched by the addition of 2 mM PMSF 
146 
 
(final concentration). After PK digestion, samples were ultracentrifuged at 120,000 X 
g for 2 h using an Optima Max Ultracentrifuge (Beckman-Coulter, Brea, CA) to pellet 
the PK-resistant fraction. The supernatant was discarded and 30 µl of PAGE loading 
buffer with DTT was added directly to the pellet. The samples were then sonicated 
for 5 mins in a cup horn sonicator, boiled for 10 mins, and separated by SDS-PAGE 
on a 15% polyacrylamide gel and transferred to nitrocellulose membrane. The 
membranes were treated with 6H4 anti-PrP monoclonal antibody overnight at 4ºC. 
6H4 antibody has been used extensively to detect the PK resistant core of the 
pathogenic PrPSc (Enari et al., 2001; Flechsig et al., 2000; Montrasio et al., 2000; 
Moynagh and Schimmel, 1999; Zou et al., 2004). Membranes were then incubated 
with HRP-conjugated secondary anti-mouse IgG antibody for 1 h at room 
temperature. Detection was done with an ECL detection kit and visualized using x-
ray film (Kodak, Rochester, NY).  
 
Quantative real time polymerase chain reaction (qRT-PCR) 
 
Total RNA was isolated from uninfected and RML scrapie-infected C57Bl/6 
mice using an Absolutely RNA Miniprep Kit. Reverse transcription into first strand 
complimentary DNA was done using a RT2 First Strand kit. Quantitative PCR was 
done with a MX3000P RT-PCR thermocycler (Stratagene, La Jolla, CA) using a 
qPCR primer assay specific for murine Prkcd. Amplification was performed over 40 
cycles and quantified as fold increase calculated by 2^(-∆∆Ct) (∆∆Ct  = ∆Ct (Mn) - 
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∆Ct (Con) as recommended by the manufacturer. 18S RNA was used as a loading 
control to ensure equal RNA levels per well.   
 
Behavioral evaluations 
 
Extensive neuronal loss during the course of transmissible spongiform 
encephalopathy (TSE) produces progressive motor deficits in humans and animals 
including ataxia, tremor, and postural instability. Grip stamina and motor control 
were evaluated using the horizontal bar test (Guenther et al., 2001; Mallucci et al., 
2007). Each mouse was held by the tail and allowed to grip a 0.2 cm diameter brass 
rod 50 cm above a padded cage with its forelimbs. The padded Innovive (San 
Francisco, CA, USA) mouse cage was placed below the bar to protect the mice from 
injury by falling. The mouse was quickly released and the time it took for the mouse 
to fall was recorded. Scores were given based on the following paradigm: 0-5s = 1; 
6-10s = 2; 11-20s = 3; 21-29s = 4; and 30s or reaching the side support = 5. 
The Columbus Instrument (Columbus, OH, USA) grip strength meter was 
used to determine the maximal amount of force each animal was apply to a specially 
designed bar with their forelimbs (LaMonte et al., 2002; Lepore et al., 2008). For all 
measurements, gauge was measured in PEAK mode and units were set to kgF. 
Animals were gripped firmly but gently at the base of the tail and the animal’s 
forelimbs were placed on grip bar. Once the animal gripped the bar with both 
forelimbs, it was steadily pulled directly away from the digital strength meter. This 
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process was repeated 2-3 times to get peak strength reading. 
Behavioral evaluations were done by trained personnel in cooperation with 
Iowa State University Laboratory Animal Resources. We evaluated uninfected and 
RML scrapie-infected C57Bl/6 and PKCδ(-/-) mice once weekly for differences in 
motor signs that reflected difficulty initiating ambulatory activities and changes in 
ambulatory activity patterns. Motor performance was scored on a scale from 0 to 4 
with 0 = normal movement, 1 = slight alteration in ambulation, 2 = obvious 
intermittent motor signs, 3 = continuous pronounced motor signs, and 4 = almost 
complete lethargy. Test animals were monitored for changes in behavioral motor 
deficits over a period of several minutes. Mice were also evaluated for clasping of 
limbs when held aloft by the tail. 
 
Data Analysis 
 
Statistical analysis was performed with Prism 4.0 software (GraphPad 
Software, San Diego, CA). Statistical analysis between uninfected and infected data 
sets were done using Student’s t-test and is indicated as follows: @p<0.1, *p<0.05, 
**p<0.01, and ***p<0.001. Data typically represent three to four separate 
experiments and are expressed as mean ± S.E.M. 
 
 
 
149 
 
Results 
  
PKCδ is proteolytically activated in RML scrapie-infected mice 
  
Apoptosis has been identified as the probable cause of neuronal loss 
associated with spongiform neurodegeneration (Bourteele et al., 2007; Carimalo et 
al., 2005; Fairbairn et al., 1994; Hetz et al., 2003; Offen et al., 2000). During 
apoptosis in neuronal cells induced by a variety of stimuli, PKCδ is cleaved by 
capsase-3 to produce a constitutively active catalytic fragment (Kanthasamy et al., 
2003; Reyland, 2007). In order to evaluate the proteolytic activation of PKCδ during 
TSE disease progression, we examined murine-adapted RML scrapie-inoculated 
mice at 60, 90, 120, and 150 dpi for the presence of the cleaved fragment of PKCδ 
by immunoblot analysis. An increase in cleaved PKCδ in RML scrapie-infected 
animals when compared to mock infected mice was observed in the early preclinical 
stages of TSE (60 and 90 DPI) in the motor cortex (Figure 1A), although the 
difference was not statistically significant (p>0.05). However, a significant increase in 
cleaved PKCδ was detected in the striatum of infected animals at 120 DPI (Figure 
1B). Although a peak in cleaved PKCδ was observed at 90 DPI in the thalamus, it 
was not statistically significant (p>0.05) (Figure 1C). Interestingly, the pons showed 
a significant decrease at 150 DPI compared to WT (Figure 1D). No cleavage was 
detected in the medulla oblongata at any time point (Figure 1 E). However, in the 
cerebellum cleaved PKCδ was evident at both 90 and 120 DPI of infected mice, 
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although only the 120 DPI time point was significant (Figure 1F). 
Previous studies have found a reduction in native PKCδ protein levels during 
the terminal stage of TSE in mice and humans (Rodriguez et al., 2005; Rodriguez et 
al., 2006). A significant decrease in native PKCδ was detected at 150 DPI in the 
motor cortex, striatum, and pons, but not in the thalamus, medulla oblongata, and 
cerebellum of RML scrapie-infected animals compared to mock (Figure 1A-F). A 
surprising increase in native PKCδ was found in the striatum at 120 DPI (Figure 1B) 
and the medulla oblongata at 90 DPI (Figure 1E). 
 
PKCδ phosphorylations at T505 and Y311 are altered during murine scrapie 
 
We systematically examined the phosphorylation of PKCδ at two regulatory 
sites: T505 within the activation loop and Y311 flanking the caspase-3 cleavage site 
of PKCδ. Phosphorylation of T505 is associated with an increase in native kinase 
activity and may induce an antiapoptotic effect (Brodie and Blumberg, 2003; Orosco 
et al., 2006). Y311 phosphorylation has been associated with the proteolytic 
activation of PKCδ (Konishi et al., 1997). Mutation of this tyrosine residue prevents 
proteolytic activation of PKCδ by caspase-3 and protects neurons from apoptosis 
induced by oxidative stress (Kaul et al., 2005). A significant increase in T505 
phosphorylation was detected in the motor cortex of RML scrapie-infected mice at 
120 DPI (Figure 2A). Despite a slight increase in cleaved PKCδ at 60 and 90 DPI, no 
increase in Y311 phosphorylation was detected in the motor cortex of infected mice 
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at any timepoint. When normalized to native PKCδ protein levels, a significant 
decrease was detected at both phospho sites at 60 DPI.  
In the striatum of infected mice, an increase in p-Y311 was detected that 
corresponds to the cleavage of PKCδ at 120 DPI (Figure 2B). An increase in p-T505 
was detected at this time point as well. However, at 60 and 150 DPI p-T505 was 
significantly decreased in comparison to uninfected animals. When normalized to 
native PKCδ protein levels, p-Y311 became significantly reduced in comparison to 
the striatum of uninfected animals indicating that the phosphorylation of Y311 within 
the striatum may be context and/or cell type specific.  
In the thalamus of infected animals, p-T505 was decreased compared to 
mock uninfected at 120 and 150 DPI which may indicate a loss of antiapoptotic 
signaling at these time points (Figure 2C). Phosphorylation of Y311 was decreased 
at 60 DPI as well. However, in the pons of RML scrapie infected mice, p-Y311 was 
increased at 120 DPI, (Figure 2D) although there was not a significant increase in 
cleaved PKCδ. T505 phosphorylation was likewise increased as 150 DPI, but the 
increase was not significant until normalized to native PKCδ. There was no 
significant difference in phosphorylation at T505 in the medulla oblongata of mock 
and scrapie-infected animals (Figure 2E). However, there was a significant decrease 
in p-Y311 when normalized to native protein levels. In the cerebellum of infected 
mice we found increased p-T505 at 60 DPI compared to control but no significant 
change at any time point after that. We additionally found an increase in p-Y311 at 
90 and 120 DPI (Figure 2F). The phosphorylation of Y311 in the cerebellum 
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corresponds to the increases in PKCδ cleavage at 90 and 120 DPI.  
 
PKCδ kinase activity is persistently activated in RML scrapie-infected mice 
 
To confirm increased DAG-independent kinase activity of PKCδ cleaved 
fragments in RML infected mouse brain, PKCδ was immunoprecipitated from the 
homogenate of the motor cortex at 60 DPI and thalamus at 90 DPI using a PKCδ 
polyclonal antibody. In order to visualize the level of kinase activity in the 
immunoprecipitated protein, the known substrate of PKCδ, histone 2B, was added 
along with 32P-ATP, with or without DAG. The samples were then run on a 12% 
polyacrylamide gel and imaged using a Fujifilm FLA-5100 phosphoimager (Fujifilm 
Life Science, Woodbridge, CT). Figure 3B shows a significant increase in DAG-
independent phosphorylation activity in the RML infected thalamus at 90 dpi 
(p<0.01). An increase in the kinase activity in the motor cortex was evident at 60 dpi 
however the p value was slightly above 0.05 (Figure 3A). The presence of kinase 
activity in the absence of DAG is indicative of persistent kinase activity in the motor 
cortex and thalamus of mice infected with RML scrapie and corresponds to 
proteolytic activation of PKCδ.  
 
The decrease in PKCδ native protein levels at 150 DPI is not transcriptionally 
regulated 
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During the terminal stages of both BSE in transgenic mice and in human CJD, 
Rodríguez and colleagues observed a reduction in native PKCδ protein expression 
(Rodriguez et al., 2005; Rodriguez et al., 2006). However, in another study PKCδ 
mRNA was found to be upregulated in murine scrapie in a microarray experiment 
(Sorensen et al., 2008). In an effort to elucidate this discrepancy between protein 
and mRNA expression between different species during the course of TSE we 
assayed the PKCδ mRNA levels in brain regions that displayed significant decrease 
in native PKCδ protein levels at 150 DPI. Surprisingly, at this time point PKCδ 
mRNA was actually increased in striatum, but no change was detected in the motor 
cortex or pons indicating that the decrease in PKCδ protein levels is not due to 
transcriptional regulation (Figure 3C). 
 
PKCδ knockout mice display altered pattern of protease resistant PrPSc 
 
Upon conversion from PrPC to PrPSc, prion protein becomes highly resistant 
to denaturation and digestion by proteases. Therefore, limited proteolytic digestion of 
infected tissue using proteinase K (PK) and detection of PrPSc by Western blot or 
ELISA has become a standard assay for the diagnosis of TSE. In order to further 
explicate the biological significance of PKCδ signaling in TSE-related apoptosis, we 
evaluated the progression of murine-adapted RML scrapie in a PKCδ knockout 
(PKCδ(-/-)) mouse line that has been used previously by our lab (Zhang et al., 
2007). Presence of PrPSc was determined by limited proteolysis of lysate from the 
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remaining cortical brain tissue using 20 µg/ml PK for one hour at 37ºC and 
subsequent Western blot. Figure 4 shows that both C57 and PKCδ(-/-) animals are 
susceptible to infection with RML scrapie. Interestingly, PKCδ(-/-) animals display an 
altered pattern of PrPSc in early stages of RML scrapie when compared to WT C57. 
Only the band corresponding to the diglycosylated glycoform of PrPSc appeared in all 
PKCδ(-/-) animals assayed at 90 DPI while all three glycoforms of PrPSc appeared in 
WT animals. Bands corresponding to all three glycoforms are apparent at 150 DPI in 
both WT and PKCδ(-/-) animals. No protease resistant PrPSc was found in mock 
infected animals. 
 
TSE-related behavioral abnormalities are delayed in PKCδ(-/-) mice 
 
The neurological symptoms of mice infected with mouse adapted scrapie 
include kyphosis, tremor, cachexia, and ataxia (Aguzzi and Heikenwalder, 2006; 
Brandner, 2003; Geissen et al., 2007; Johnson, 2005; Liberski and Brown, 2004; 
Strandberg Pedersen, 2003; Tatzelt and Schatzl, 2007; Unterberger et al., 2005; 
Wolferstan, 2003). Additionally, infected mice display clasping of limbs when held 
aloft by the tail (Wang et al., 2011). If PKCδ signaling contributes significantly to the 
neurodegeneration associated with TSE, inhibition of PKCδ function may delay 
onset of the disease. In order to further explicate the biological significance of PKCδ 
signaling in TSE-related apoptosis, we evaluated the motor function of mice 
following inoculation with murine-adapted RML scrapie in a PKCδ knockout (PKCδ(-
155 
 
/-)) mouse line that has been used previously by our lab (Zhang et al., 2007). Mice 
were evaluated weekly using the horizontal bar test and grip strength meter to 
evaluate grip strength, stamina, and coordination. Beginning at week 14, WT 
infected animals displayed a significant reduction in forelimb strength (Figure 5A). 
Conversely, PKCδ(-/-) animals retained forelimb strength comparable to uninfected 
mice until sacrificed at 150 DPI. For the horizontal bar test (Figure 5B), mice were 
scored based on the time they were able to hang from a suspended metal bar. The 
scores were as follows: 0-5s = 1; 6-10s = 2; 11-20s = 3; 21-29s = 4; and 30s or 
reaching the side support = 5. Infected WT animals began showing difficulty staying 
on the bar at week 18 but the score significantly decreased at week 21 (Figure 5B). 
PKCδ(-/-) mice showed no significant reduction during the course of infection.  
Clinical evaluation of all mice was done weekly in order to identify behavioral 
signs of RML scrapie-induced motor deficits. We evaluated both C57Bl/6 and 
PKCδ(-/-) mice for differences in motor signs that reflect difficulty initiating 
ambulatory activities and changes in ambulatory activity patterns and scored their 
pathology on a scale from 0 to 4 with 0 indicating normal movement and 4 indicating 
almost complete lethargy (Figure 5C). Test animals were monitored over a period of 
several minutes for changes in behavioral motor deficits reflecting postural instability 
and difficulty in open field ambulation. Symptoms began appearing in WT mice at 
week 17 and became progressively more pronounced over the course of monitoring 
(Figure 5C). Conversely, PKCδ(-/-) mice showed a delayed onset of TSE-related 
ataxia and a reduction in the severity of observable motor signs. Additionally, mice 
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were tested for the clasping of limbs when held aloft by the tail. PKCδ(-/-) mice 
likewise showed a delay in the onset of clasping, as well as a reduction in the 
severity (Figure 5D). Taken together, these results indicated that lack of PKCδ 
catalytic activity delayed the onset of neurological signs associated with mouse 
adapted scrapie. 
 
RML scrapie-infected PKCδ knockout mice have altered caspase-3 cleavage and 
markers of oxidative stress 
 
Markers of oxidative stress have been observed in various prion diseases 
including products of lipid peroxidation and oxidized amino acid side chains such as 
4-hydroxynonenal and 3-nitrotyrosine (Andreoletti et al., 2002; Freixes et al., 2006; 
Yun et al., 2006). The molecular pathway of apoptotic neuronal loss in TSE includes 
activation of the effector caspase-3 (Engelstein et al., 2005; Jamieson et al., 2001). 
The level of oxidative damage and subsequent caspase-3 activation were assayed 
in mock infected and RML scrapie-infected C57 and PKCδ(-/-) mouse brain regions 
at 90 and 150 DPI by Western blot analysis using anti-4-HNE and anti-caspase-3 
antibodies, respectively. At 90 DPI, oxidative damage was increased in RML 
scrapie-infected PKCδ(-/-) animals compared to WT as indicated by an increase in 
4-HNE within the motor cortex, striatum, and thalamus (Figure 6A) but not in the 
medulla oblongata and pons (Figure 6B). A slight increase in 4-HNE was also 
observed in the cerebellum, although p>0.05 for this value (Figure 6B). At 150 DPI, 
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we observed marginal increases in 4-HNE accumulation in the pons and medulla 
oblongata but not in the motor cortex, striatum, thalamus or cerebellum of RML 
scrapie-infected PKCδ(-/-) animals when compared to WT (Figures 6D and E). 
Next we measured the protein levels cleaved caspase-3, another marker of 
apoptosis by Western blot.  At 90 DPI cleaved caspase-3 was surprisingly increased 
in the striatum and thalamus (Figure 7A) but not the pons or cerebellum (Figure 7B) 
of RML scrapie-infected PKCδ(-/-) mice compared to WT (Figure 7A). However, 
cleaved caspase-3 levels were decreased in the medulla oblongata and motor 
cortex at the same time point (Figure 7A-B). However, at 150 DPI cleaved caspase-
3 was increased in motor cortex and thalamus (Figure 7C); but decreased in the 
pons and medulla oblongata of RML scrapie-infected PKCδ(-/-) mice (Figure 7D). 
These data indicate an altered pattern of apoptotic cell death and oxidative stress in 
RML scrapie-infected PKC(-/-) mice when compared to WT. 
 
RML scrapie-infected PKCδ knockout mice have an altered pattern of Fluorojade 
positive cells 
 
In order to more thoroughly examine the pattern of apoptotic neuronal loss in 
WT and PKC(-/-) mice, the motor cortex, striatum, thalamus, and cerebellum of 
terminally ill (150 DPI) were examined using Fluorojade C, a dye used to label 
degenerating neurons and activated glial cells (Damjanac et al., 2007; Ye et al., 
2001). Comparison of these histopathological changes in the various brain regions 
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of the WT and PKCδ(-/-) mice were used to identify regional differences in 
importance of PKCδ in TSE-induced apoptosis. At 150 DPI, animals were perfused 
with 4% paraformaldehyde and processed for sectioning. 30 µm sections were cut 
with a cryostat and stained as per manufacturer instructions. Mock infected WT and 
PKCδ(-/-) animals display little to no Fluorojade staining, indicating specificity of the 
Fluorojade dye for degenerating neurons and activated glial cells related to RML 
scrapie infection (Figure 8A). In RML scrapie-infected C57 animals, widespread 
Fluorojade-positive cells were evident throughout the motor cortex, striatum, 
thalamus, and cerebellum. Conversely, in PKCδ(-/-) animals, a similar distribution of 
Fluorojade positive cells were evident in motor cortex, striatum, and thalamus; 
however, in motor cortex and striatum many of these cells displayed altered 
morphology from WT animals (Figure 8B). Both morphology as well as distribution of 
Fluorojade-positive cells between infected WT and PKCδ(-/-) animals were 
unchanged in the thalamus. The cerebellum of infected PKCδ(-/-) animals, on the 
other hand, showed marked reduction of Fluorojade positive cells (Figure 8B). 
 
Discussion 
 
In the present study we report activation of PKCδ by proteolytic cleavage 
during the course of murine scrapie in multiple brain regions. Upon cleavage by 
caspase-3, the catalytic domain of PKCδ translocates to different cellular organelles 
including the nucleus, mitochondria, and plasma membrane and induces apoptosis, 
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although the exact substrates involved in this cascade are still under investigation.  
(Kanthasamy et al., 2003; Kikkawa et al., 2002; Kitazawa et al., 2005; Reyland, 
2007; Yang et al., 2004). The incidence of PKCδ cleavage prior to the onset of 
clinical symptoms and accumulation of PrPSc in mice infected with RML scrapie 
coincides with studies that have detected signs of oxidative stress in mice infected 
with TSE prior to the development of clinical pathology (Yun et al., 2006). 
We have further characterized the decrease in PKCδ protein levels in terminal 
TSE first described by Rodriguez and colleagues (Rodriguez et al., 2005; Rodriguez 
et al., 2006). The changes in the protein level of PKCδ during the course of TSE are 
seemingly not correlated to transcriptional regulation. This discrepancy between 
transcriptional regulation and protein expression may be due to pathogenic 
modulation of the protein degradation systems. Disruption of the ubiquitin 
proteosomal system (UPS) has long been linked to various amyloidogenic 
proteinopathies (Tyedmers et al., 2010). Intracellular oligomeric aggregation of 
proteins directly inhibit the UPS and have been implicated in disease pathogenesis 
(Bence et al., 2001; Bennett et al., 2005; Holmberg et al., 2004). Widespread 
changes in the specificity and function of the UPS and sequesteration of signaling 
molecules may cause ectopic function and promote neurodegeneration. Additionally, 
expression of PKCδ sensitizes neuronal cells to oxidative stress (Marengo et al., 
2011). Neurons expressing higher levels of PKCδ may be more susceptible to TSE-
related oxidative stress and undergo apoptoic cell death during earlier stages of the 
disease. Therefore reduced levels of PKCδ found in the later stages of TSE may be 
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a result of the loss of cells that normally express higher levels of PKCδ. 
A recent study uncovered evidence that caspase activation and PKCδ 
cleavage mediate microglial activation and therefore promote neuroinflammation 
(Burguillos et al., 2011). Widespread microglial activation and astrogliosis have been 
observed in various models of TSE (Diedrich et al., 1991). The delay in the onset of 
clinical symptoms of TSE in PKCδ(-/-) animals observed in this study as a result of 
an attenuation in TSE-related inflammatory events cannot be ruled out. The change 
in distribution of cleaved caspase-3 and the observed difference in the cell 
morphology of Fluorojade-positive cells in the striatum and motor cortex of RML 
scrapie-infected PKC(-/-) animals compared to WT may indicate these cells are 
activated astrocytes since Fluorojade is known to stain not only degenerating 
neurons, but activated glial cells as well. These results may indicate an altered 
pattern of TSE-related inflammatory neuroinflammation in PKCδ(-/-) animals. 
However, a more detailed investigation is needed to elucidate altered glial activation 
as a result of PKCδ inhibition. 
Despite the increase in markers of oxidative damage and activation of 
caspase-3 we observed in some brain regions of PKCδ(-/-) animals infected with 
RML scrapie, the lack of PKCδ catalytic activity in mutant mice delayed the onset of 
motor deficits associated with TSE and may be a potential target for pharmaceutical 
intervention. A study done by our lab indicated that the PKCδ inhibitor rottlerin 
protects mice treated with the Parkinsonian toxin MPTP, a known inducer of 
oxidative stress (Zhang et al., 2007). Animals treated with rottlerin had increased 
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locomotor function and dopamine levels when compared to animals only treated with 
toxin. The successful attenuation of scrapie-induced neurodegeration by 
pharmacological inhibitors of PKCδ could provide a basis for the development of 
effective therapies prior to the onset of widespread spongiform neurodegeneration 
and motor deficits in TSE. 
In conclusion, we have identified altered regulatory phosphorylation and 
proteolytic activation of PKCδ in multiple brain regions at various time points during 
the progression of mouse adapted scrapie. Knockout of PKCδ resulted in a delayed 
onset of scrapie-induced motor symptoms and an altered pattern of markers of 
oxidative damage and neurodegeneration. Detailed mechanistic studies will help to 
elucidate the context specific contribution of PKCδ to the neurodegenerative and 
neuroinflammatory processes during the course of prion disease. 
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Figure 1. PKCδ is proteolytically activated during murine scrapie. The protein 
levels of native and cleaved of PKCδ were examined by immunoblot in RML scrapie 
infected mice at 60, 90, 120, and 150 DPI. C57/Bl6 mice were infected by i.c. 
injection of 30 µl of 1% infected brain homogenate. Control mock inoculations were 
done with 1% brain homogenate from uninfected mice.  A) In motor cortex of 
infected animals, PKCδ cleavage was slightly increased at 60 DPI and slightly 
decreased at 150 DPI compared to mock (p<0.1 for both). Native PKCδ protein 
levels were decreased at 150 DPI (p<0.05). B) Cleaved PKCδ was significantly 
increased in the striatum at 120 DPI (p<0.01) and decreased at 150 DPI (p<0.05). 
Changes in the native protein level correlated with these changes (p<0.05). C) 
Cleaved PKCδ levels were increased in the thalamus of animals at 90 DPI, and 
decreased at 120 DPI, though not significantly (p<0.1). D) In pons, both native and 
cleaved levels were significantly reduced at 150 DPI (p<0.001 and p<0.05, 
respectively). E) Native PKCδ levels were significantly increased in medulla 
oblongata at 150 DPI (p<0.05). No cleaved PKCδ was detectable levels at any time 
point. F) In cerebellum, there was increased PKCδ cleaveage PKCδ at 90 (p<0.1) 
and 120 (p<0.05) and a significant decrease at 150 DPI (p<0.05). Data represent 
mean ± SEM from densitometric analysis of immunoblots from three separate 
animals. 
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Figure 2. PKCδ p-T505 and p-Y311 levels in RML scrapie-infected mice.  The 
phosphorylation of PKCδ at T505 and Y311 was examined by immunoblot in RML 
scrapie-infected animals at 60, 90, 120, and 150 DPI. C57/Bl6 mice were infected by 
i.c. injection of 30 µl of 1% infected brain homogenate. Mock inoculations were 
performed using 1% brain homogenate from uninfected mice. A) The 
phosphorylation at T505 was increased in the motor cortex of infected animals at 
120 DPI (p<0.05). When normalized to native protein levels p-T505 levels were 
significantly lower than mock infected at 60 DPI (p<0.01) as was the site at Y311 
(p<0.01). However, the phosphorylation of Y311 was increased at 150 DPI (p<0.05). 
B) Phosphorylation at T505 was decreased at 60 and 150 DPI in the striatum of 
infected animals (p<0.05). However, both T505 (p<0.01) and Y311 (p<0.01) were 
significantly increased at 120 DPI. The increase in p-T505 becomes no change and 
the increase in p-Y311 becomes a significant reduction (p<0.01) when normalized to 
native protein levels, indicating the specificity of both signals. C) In the thalamus of 
infected animals, Y311 phosphorylation was decreased at 60 DPI (p<0.05), and 
T505 was decreased at both 120 (p<0.05) and 150 DPI (p<0.05). D) A significant 
increase in the pons of infected animals was observed in p-Y311 at 120 DPI 
(p<0.05). When normalized to native protein levels, p-Y311 is slightly but 
significantly increased at 60 DPI (p<0.05). Additionally, p-T505 was increased at 150 
DPI but the densitometric value was not significant until normalized to native protein 
levels (p<0.01). This is most likely due to the large variation among animals. E) The 
only significant change in the medulla oblongata of infected mice was a decrease in 
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Y311 phosphorylation at 90 DPI when normalized to native protein levels (p<0.05). 
F) There were several changes in cerebellar phosphorylation of PKCδ in infected 
animals. Y311 phosphorylation was decreased early at 60 DPI (p<0.05), but 
increased at 90 (p<0.001) and 120 DPI (p<0.05), before again decreasing at 150 
DPI (p<0.05). These changes corresponded exactly to the cleavage of PKCδ. 
Additionally, p-T505 was significantly increased at 60 DPI (p<0.05). Levels of 
statistical significance are marked as follows: @ p<0.1, * p<0.05, ** p<0.01 and *** 
p<0.001. Data represent mean ± SEM of densitometric analysis of immunoblots from 
four separate animals. 
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Figure 3. PKCδ kinase activity is increased in RML scrapie-infected animals 
and changes in PKCδ native protein level are not transcriptionally regulated. 
A-B) Kinase activity was measured by 32P kinase assay using PKCδ 
immunoprecipitated from the motor cortex at 60 DPI and the thalamus at 90 DPI of 
mock and RML scrapie-infected animals. DAG-independent kinase activity was 
increased both regions indicating persistent activation of PKCδ; however in motor 
cortex the p value was slightly above 0.05. Data represent mean ± SEM of 
densitometric analysis from phosphoimage of three separate animals.C) Total RNA 
was isolated from uninfected and RML scrapie-infected mouse brain regions at 150 
DPI. RNA was quantified by NanoDrop and RNA levels were equalized. Reverse 
transcription was done to produce cDNA and the level of PKCδ mRNA was assayed 
by SYBR-green real time quantitative PCR analysis. Although we observed an 
decrease in the PKCδ native protein levels in the motor cortex and pons, we 
observed no change in the mRNA levels at 150 DPI. The striatum of RML scrapie-
infected mice actually displayed a slight but significant increase in PKCδ mRNA 
levels despite a significant decrease in protein levels. Asterix indicate statistical 
significance levels of * p<0.05, ** p<0.01, and *** p<0.001. Data represent mean ± 
SEM from three individual animals each with two replicates.  
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Figure 4. RML scrapie-infected WT and PKCδ knockout animals accumulate 
protease resistant PrPSc. C57Bl/6 and PKCδ(-/-) animals were inoculated i.c. with 
RML scrapie. At 90 and 150 DPI animals were sacrificed and cortical lysate (not 
including the motor and frontal cortices) was subjected to limited proteolysis by 
addition of 20 µg/ml PK and incubation at 37ºC for 1 h. The presence of protease 
resistant PrPSc was determined by SDS-PAGE and immunoblot analysis with anti-
PrP MAb. In mock inoculated animals, no PrPSc was observable, while in both WT 
and PKC(-/-) at 90 (A) and 150 (B) DPI protease resistant PrPSc was evident. In two 
of the three PKCδ(-/-) animals assayed at 90 DPI, an altered pattern of protease 
resistant PrP was observed. At 150 DPI, all RML scrapie-infected animals displayed 
the same three bands corresponding to the three different glycoforms of PrPSc. Data 
represent limited proteolysis of three separate animals. 
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Figure 5. PKCδ knockout mice display delayed onset of RML scrapie-related 
motor symptoms. RML scrapie-infected WT and PKCδ(-/-) mice were evaluated for 
motor changes weekly after inoculation. A) Forelimb grip strength was measured 
using a grip strength meter. WT animals began to display significantly reduced grip 
strength beginning at 14 weeks. RML scrapie-infected PKC(-/-) animals displayed no 
significant change from mock infected WT and PKC(-/-) animals throughout the 
course of infection. B) Motor function was evaluated using the horizontal bar test. 
WT RML scrapie-infected mice began to show deficits at 17 weeks, and changes 
became significant at 21 weeks. RML scrapie-infected PKCδ(-/-) mice and mock 
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infected mice showed no significant changes. Scores were given based on the time 
each animal could remain hanging from the bar: 0-5s = 1; 6-10s = 2; 11-20s = 3; 21-
29s = 4; and 30s or reaching the side support = 5 C) Mice were evaluated for open 
field ambulation and ability to initiate movement over the course of several minutes. 
Slight changes in motor function were observed in infected WT mice beginning at 18 
weeks and progressed to moderate by 20 weeks. Conversely, PKCδ(-/-) mice 
displayed a delayed onset in motor signs, and changes remained mild throughout 
monitoring period. D) The clasping of limbs when held aloft by the tail was evaluated 
in WT and PKCδ(-/-) mice. Clasping symptoms began in WT mice at 14 weeks and 
steadily progressed to severe over the course of monitoring. PKCδ(-/-) animals did 
not begin clasping of limbs until 17 weeks and  symptoms did not progress past mild 
over the course of monitoring. Data represent mean ± SEM with each group 
containing 6-8 male and female animals.  
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Figure 6. RML scrapie-infected PKCδ knockout animals display increased 
markers of oxidative damage. The level of oxidative damage was evaluated in 
RML scrapie-infected WT and PKCδ(-/-) animals by immunoblot for 4-HNE, a 
product of lipid peroxidation. A and B) Significant increases in 4-HNE accumulation 
were observed in RML scrapie-infected PKCδ(-/-) animals compared to WT in motor 
cortex, striatum, thalamus, and hippocampus. A slight increase was also observed in 
cerebellum but was under the level of significance. B  and D) A significant increase 
in oxidative damage was observed in pons in PKCδ(-/-) animals at 150 DPI. A slight 
but not significant increase was also observed in medulla oblongata. Levels of 
statistical significance are marked as follows: @ p<0.1 * p<0.05 ** p<0.01 *** 
p<0.001. Data represent mean ± SEM of densitometric analysis from immunoblots of 
three separate animals. 
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Figure 7. RML scrapie-infected PKCδ knockout mice have an altered pattern of 
caspase-3 activation. RML scrapie-infected WT and PKCδ(-/-) mice were 
evaluated for activation of caspase-3 by immunoblot analysis for the presence of 
cleaved caspase-3. A and B) At 90 DPI PKC(-/-) animals have an increase in 
caspase-3 activation in the striatum and thalamus, but a decrease in the medulla 
oblongata. C and D) At 150 DPI, PKC(-/-) animals have a similiar increase in 
caspase-3 activation in the motor cortex and thalamus, but a decrease in the pons 
as well as the medulla oblongata. Levels of statistical significance are marked as 
follows: @ p<0.1 * p<0.05 ** p<0.01 *** p<0.001. Data represent mean ± SEM of 
densitometric analysis from immunoblots of three separate animals. 
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Figure 8. RML scrapie-infected PKCδ(-/-) mice display an altered pattern of 
Fluorojade staining. Degenerating neurons were identified by Fluorojade staining 
at 150 DPI in mock and RML scrapie-infected WT and PKCδ(-/-) mice. A) Mock 
infected WT and PKCδ(-/-) mice display little to no Fluorojade staining in all brain 
regions examined by fluorescent microscope. B) RML scrapie-infected WT animals 
display widespread Fluorojade staining in all brain regions examined. RML scrapie-
infected PKCδ(-/-) mice display strong staining in the motor cortex, striatum, and 
thalamus but show a reduction in Fluorojade-positive cells in the cerebellum. In the 
motor cortex and striatum of PKCδ(-/-) many of the Fluorojade positive cells 
displayed altered morphology compared to WT.  
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CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
The results and implications have been presented in each research chapter 
within this document. This section will provide a broad overview of the findings and 
suggest possible future studies to continue to elucidate the neurodegenerative 
mechanisms of TSE. 
 
Manganese is involved in the pathogenesis of TSE 
 
 PrPC readily binds divalent metals, and copper is specifically required during 
normal functioning of the protein (Brown, 2009).  The discovery that Mn was 
increased during the course of TSE in both humans and animals and that it could 
replace copper despite an apparent lower affinity implicated this metal in the 
pathogenesis of the disease (Hesketh et al., 2007; Hesketh et al., 2008; Thackray et 
al., 2002). Additionally, PrPSc infected cells were shown to be more susceptible to 
oxidative stress suggesting the possibility that direct Mn toxicity might be responsible 
for TSE-related neuronal loss (Milhavet et al., 2000). Instead our findings in cell 
culture models indicate that PrPSc infected cells are in fact less susceptible to Mn 
toxicity. PrPSc infected CAD5 cells had less caspase-3 activation, DNA 
fragmentation, and less accumulation of intracellular Mn. These results provide 
evidence that increased Mn during the course of TSE may affect pathogenesis in 
some other fashion besides direct toxicity. Truncation studies or mutation of the 
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active His residues within the metal binding sites would help to identify the role of the 
specific metal binding sites of PrPC, including the octapeptide repeat domain and 
the 5th site. 
 We further found that Mn treatment induces an increase in the cytosolic 
localization of PrPC. This finding is significant because it provides a mechanism 
whereby cytosolic Mgrn1 and GPI-anchored PrPC could interact during disease 
pathogenesis. Mgrn1 E3 ubiquitin ligase activity has been implicated in not only 
polyubiquitination of substrate proteins to signal degradation in the proteasome, but 
also monoubiquitination and vesicle trafficking (Cooray et al., 2011; Kim et al., 2007; 
Perez-Oliva et al., 2009). It is important going forward to establish not only the direct 
cytosolic interaction of Mgrn1 and cytosolic PrP as a result of Mn treatment, but also 
the attenuation of Mgrn1 E3 ubiquitin ligase activity. A recent study found that the 
level of Mgrn1 does not affect the progression of mouse adapted scrapie in an 
animal model of TSE, indicating that Mgrn1 function has redundancy (Silvius et al., 
2013). Additionally, it is important to note that both infected and uninfected cells 
displayed cytosolic PrP at the same time points despite having different tolerances 
to Mn toxicity. The requirement for the presence of PrPSc may also be ascertained 
as well as the specific metal binding site(s) required for this mechanism. While we 
have discovered that infection with PrPSc alters a Mn-induced increase in Mgrn1 
protein levels in CAD5 cells, additional time points are needed for a detailed qRT-
PCR study to clarify the transcriptional regulation of Mgrn1 in response to Mn 
treatment. 
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Figure 1 Hypothetical scheme of Mn-induced cytosolic PrP Interaction with 
Mgrn1. Exposure to increased Mn concentrations induces increased cytosolic PrP 
levels through endocytosis into early endosomal vesicles or another unidentified 
mechanism. Interaction with cytosolic PrPC or PrPSc allosterically inhibits the E3 
ubiquitin ligase function of Mgrn1 leading to dysfunction of the UPS and spongiform 
degeneration indicative of TSE.  
 
Kinase signaling modulates TSE neurodegeneration 
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 Our finding that PKCδ is proteolytically activated during TSE draws further 
connections between prion-like neurodegenerative disorders such as Parkinson’s 
disease and TSE since PKCδ is a key mediator of neuronal apoptosis in 
dopaminergic neurons (Kanthasamy et al., 2003; Reyland, 2007). Although PKCδ 
activation may be occurring within degenerating neurons to promote apoptosis in 
TSE, the possibility remains that these events are also occurring in activated glial 
cells to promote neuroinflammation. A recent study has shown a connection 
between caspase-3-mediated cleavage of PKCδ and activation of microglia 
indicating that glial cells may be a site of cleaved PKCδ (Burguillos et al., 2011). 
Future studies dedicated to pinpointing the location of PKCδ cleavage and internal 
phosphorylation events must be done to continue to elucidate the role of this key 
protein kinase in TSE-related neurodegeneration. A lack of viable in vitro model 
systems that accurately model TSE has hampered more detailed mechanistic 
investigations. The recent development of murine scrapie infected ex vivo brain slice 
cultures and adult primary culture of neurons that propagate prion infection may 
allow for more high throughput mechanistic studies (Falsig et al., 2008; Grassmann 
et al., 2013). Previously, our group has shown that the PKCδ inhibitor rottlerin 
protected mice treated with the Parkinsonian toxin MPTP, leading to increased 
locomotor function and dopamine levels (Zhang et al., 2007). Similar studies in 
models of TSE using rottlerin or its analogs may provide a one of the first viable 
treatment options for those infected with prion disease.  
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Overall, the results presented in this document provide some new 
understanding of the neurodegenerative mechanisms of TSE. Few potential targets 
for the development of future therapies for TSE in both humans and animals have 
been presented, and await further studies. 
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